Amedeo Smart

Free Medical Literature Service


 

Amedeo

Dermatology

  Free Subscription

Articles published in
Br J Dermatol
    June 2024
  1. BENCOMO T, Lee CS
    Gene expression landscape of cutaneous squamous cell carcinoma progression.
    Br J Dermatol. 2024 Jun 13:ljae249. doi: 10.1093.
    >> Share

  2. BARBAROT S, Aubert H, Vibet MA, Leray M, et al
    Effectiveness of a nurse-led one-to-one education programme in addition to standard care in children with atopic dermatitis: a multicentre randomized control trial.
    Br J Dermatol. 2024 Jun 12:ljae111. doi: 10.1093.
    >> Share

  3. FISCHER J
    Confetti Cure: Reversing the Genetic Kaleidoscope of Ichthyosis.
    Br J Dermatol. 2024 Jun 11:ljae248. doi: 10.1093.
    >> Share

  4. VENABLES ZC, Wakkee M
    Basal cell carcinoma incidence trends - can we stop the surge?
    Br J Dermatol. 2024 Jun 5:ljae239. doi: 10.1093.
    >> Share

  5. LOUVEAU B, Nakouri I, Jouenne F, Baroudjian B, et al
    Genomic profiling of a skin adnexal carcinomas cohort using a comprehensive high throughput sequencing approach.
    Br J Dermatol. 2024 Jun 5:ljae233. doi: 10.1093.
    >> Share

  6. GUTTMAN-YASSKY E, Croft M, Geng B, Rynkiewicz N, et al
    The role of OX40L/OX40 axis signalling in atopic dermatitis.
    Br J Dermatol. 2024 Jun 5:ljae230. doi: 10.1093.
    >> Share

  7. FUJIMURA T, Yoshino K, Kato H, Fukushima S, et al
    Phase II, multicenter study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-PD-1 antibody-refractory malignant melanoma: TM5614-MM trial.
    Br J Dermatol. 2024 Jun 4:ljae231. doi: 10.1093.
    >> Share

    May 2024
  8. KISS O, Bahri R, Watson REB, Chike C, et al
    The impact of irritant challenge on the skin barrier and myeloid resident immune cells in post-menopausal women is modulated by hormone replacement therapy.
    Br J Dermatol. 2024 May 31:ljae226. doi: 10.1093.
    >> Share

  9. CHOI ME, Choi EJ, Lee JH, Won CH, et al
    Spatial transcriptome analysis of amelanotic acral melanoma reveals distant molecular determinants compared to pigmented acral melanoma.
    Br J Dermatol. 2024 May 30:ljae224. doi: 10.1093.
    >> Share

  10. SHEN CH, Yang YS, Lee IT, Chiang MH, et al
    Sodium-glucose cotransporter protein-2 inhibitors for diabetes and the reduced risk of inflammatory skin diseases.
    Br J Dermatol. 2024 May 29:ljae229. doi: 10.1093.
    >> Share

  11. BARBIERI A, Orloff J, Gulati N, Brown RM, et al
    Living in my own skin: dermatological concerns and gender-affirming care as a trans person with neurofibromatosis type 1.
    Br J Dermatol. 2024 May 27:ljae170. doi: 10.1093.
    >> Share

  12. VAHER H
    Expanding the knowledge about the TNF-alpha induced GSDME-mediated pyroptosis in psoriasis.
    Br J Dermatol. 2024 May 23:ljae223. doi: 10.1093.
    >> Share

  13. LUO L, Cheng H, Liu Z, Olszewski P, et al
    Single-cell transcriptomic analysis identifies infiltrating plasmacytoid dendritic cells in psoriasis epidermis.
    Br J Dermatol. 2024 May 22:ljae210. doi: 10.1093.
    >> Share


  14. Correction to: Loss-of-function variants in GLMN are associated with generalized skin hyperpigmentation with or without glomuvenous malformation.
    Br J Dermatol. 2024 May 22:ljae212. doi: 10.1093.
    >> Share

  15. FRYSZ M, Patel S, Li MOY, Griffiths CEM, et al
    Prevalence, incidence, mortality, and healthcare resource use for generalised pustular psoriasis, palmoplantar pustulosis, and plaque psoriasis in England: a population-based cohort study.
    Br J Dermatol. 2024 May 22:ljae217. doi: 10.1093.
    >> Share

  16. HANRAHAN GB, Tsibris HC
    Mutational Landscape and Tumor Mutational Burden in Adult Patients with Malignant Melanoma Arising From Congenital Nevi.
    Br J Dermatol. 2024 May 21:ljae214. doi: 10.1093.
    >> Share

  17. MORREL B, Kampherbeek JHJ, Ten Kate-Booij MJ, van der Avoort IAM, et al
    Growing up with juvenile vulvar lichen sclerosus, the experiences and care needs of adult women with lichen sclerosus since childhood: a qualitative exploration.
    Br J Dermatol. 2024 May 21:ljae203. doi: 10.1093.
    >> Share


  18. Correction to: Breastfeeding decreases the risk of developing psoriasis through to early adulthood.
    Br J Dermatol. 2024 May 20:ljae208. doi: 10.1093.
    >> Share


  19. Contact allergies to dental material.
    Br J Dermatol. 2024;190:e66.
    >> Share


  20. Predicting the likelihood of hidradenitis suppurativa disease progression based on identified risk factors.
    Br J Dermatol. 2024;190:e67.
    >> Share


  21. The impact of atopic dermatitis on children and adolescents.
    Br J Dermatol. 2024;190:e65.
    >> Share


  22. Incidence, mortality and survival in people with Merkel cell carcinoma: a systematic review.
    Br J Dermatol. 2024;190:e64.
    >> Share

  23. PAVLENKO D, Akiyama T
    Cryosim-1: a cool solution for acute and chronic itch.
    Br J Dermatol. 2024;190:787.
    >> Share

  24. THANG CJ, Garate D, O'Leary S, Golovko G, et al
    Evaluation of the association between tetracycline-class antibiotic use in patients with acne and idiopathic intracranial hypertension risk: a population-level cohort study.
    Br J Dermatol. 2024;190:921-923.
    >> Share

  25. JAMES M, Nakamura M, Whittaker S, Morris S, et al
    Mycosis fungoides: successful re-treatment with brentuximab vedotin.
    Br J Dermatol. 2024;190:929-930.
    >> Share

  26. ZOUBOULIS CC, Passeron T, Pariser D, Wozniak MB, et al
    Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.
    Br J Dermatol. 2024;190:836-845.
    >> Share

  27. KIM DY
    Mortality landscape of Behcet disease.
    Br J Dermatol. 2024;190:784.
    >> Share

  28. BAHAR F, DeCaprio JA
    Why do we distinguish between virus-positive and virus-negative Merkel cell carcinoma?
    Br J Dermatol. 2024;190:785-786.
    >> Share

  29. LIAO V, Cornman HL, Ma E, Kwatra SG, et al
    Prurigo nodularis: new insights into pathogenesis and novel therapeutics.
    Br J Dermatol. 2024;190:798-810.
    >> Share

  30. LEE S, Wei ET, Selescu T, Babes A, et al
    Histamine- and pruritogen-induced itch is inhibited by a TRPM8 agonist: a randomized vehicle-controlled human trial.
    Br J Dermatol. 2024;190:885-894.
    >> Share

  31. GORDON ER, Trager MH, Kontos D, Weng C, et al
    Ethical considerations for artificial intelligence in dermatology: a scoping review.
    Br J Dermatol. 2024;190:789-797.
    >> Share

  32. CHOI SR, Shin A, Ha YJ, Lee YJ, et al
    All-cause and cause-specific mortality in patients with Behcet disease versus the general population.
    Br J Dermatol. 2024;190:858-866.
    >> Share

  33. JOHNSON O
    Living with nodular prurigo.
    Br J Dermatol. 2024;190:915.
    >> Share

  34. GREKOWITZ E, Metz M, Altrichter S, Bauer A, et al
    Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial.
    Br J Dermatol. 2024;190:825-835.
    >> Share

  35. MARONESE CA, Marzano AV
    Identifying candidates for early intervention in hidradenitis suppurativa.
    Br J Dermatol. 2024;190:787-788.
    >> Share

  36. RAGAMIN A, Zhang J, Pasmans SGMA, Schappin R, et al
    The construct validity, responsiveness, reliability and interpretability of the Recap of atopic eczema questionnaire (RECAP) in children.
    Br J Dermatol. 2024;190:867-875.
    >> Share

  37. TORRE-CASTRO J, Rodriguez M, Alonso-Alonso R, Mendoza Cembranos MD, et al
    LT and SOX9 expression are associated with gene sets that distinguish Merkel cell polyomavirus (MCPyV)-positive and MCPyV-negative Merkel cell carcinoma.
    Br J Dermatol. 2024;190:876-884.
    >> Share

  38. KJAERSGAARD ANDERSEN R, Pedersen O, Eidsmo L, Jemec G, et al
    Initial steps towards developing a predictive algorithm of disease progression for hidradenitis suppurativa (HS): results from a Cox proportional hazard regression analysis on disease progression among a cohort of 335 Danish patients with HS.
    Br J Dermatol. 2024;190:904-914.
    >> Share

  39. CHIESA FUXENCH ZC
    The burden of atopic dermatitis across paediatric populations: 'it's not just an itch that rashes'.
    Br J Dermatol. 2024;190:783-784.
    >> Share

  40. MISTRY K, Venables ZC
    A systematic review of Merkel cell carcinoma epidemiology highlights its rising incidence, poor prognosis and data heterogeneity.
    Br J Dermatol. 2024;190:782-783.
    >> Share

  41. MOHSEN ST, Price EL, Chan AW, Hanna TP, et al
    Incidence, mortality and survival of Merkel cell carcinoma: a systematic review of population-based studies.
    Br J Dermatol. 2024;190:811-824.
    >> Share

  42. OLSEN CM
    Ecological evidence for melanoma overdiagnosis in Denmark.
    Br J Dermatol. 2024 May 16:ljae206. doi: 10.1093.
    >> Share

  43. DU J, Dong C, Lin J, Lu X, et al
    MMP2hi Fibroblasts Regulate CD8+ T Cell Residency and Inflammation via CD100 in Psoriasis.
    Br J Dermatol. 2024 May 16:ljae205. doi: 10.1093.
    >> Share

  44. HAMMAS K, Nardin C, Boyer S, Michel C, et al
    Incidence and trends of first basal cell carcinomas in France between 1980 and 2019: a regional population-based registry study.
    Br J Dermatol. 2024 May 15:ljae201. doi: 10.1093.
    >> Share

  45. TANAHASHI K, Kono M, Yoshikawa T, Suzuki Y, et al
    Treating epidermolytic ichthyosis and ichthyosis with confetti with epidermal autografts cultured from revertant skin.
    Br J Dermatol. 2024 May 13:ljae193. doi: 10.1093.
    >> Share

  46. RODRIGUEZ M, Rebollo-Gonzalez M, Frutos Diaz-Alejo J, Manso R, et al
    Mutational profiling of Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorders do not resemble nodal peripheral T-cell lymphomas with follicular helper T-cell phenotype.
    Br J Dermatol. 2024 May 13:ljae192. doi: 10.1093.
    >> Share

  47. PARRAGA SP, Feldman SR
    Insulin resistance and psoriasis.
    Br J Dermatol. 2024 May 13:ljae199. doi: 10.1093.
    >> Share

  48. BOITOR RA, Varma S, Sharma A, Odedra S, et al
    Diagnostic accuracy of autofluorescence-Raman spectroscopy for surgical margin assessment during Mohs micrographic surgery of basal cell carcinoma.
    Br J Dermatol. 2024 May 13:ljae196. doi: 10.1093.
    >> Share

  49. PASSERON T, Reinhardt M, Ehst B, Weiss J, et al
    Secukinumab in adult patients with lichen planus: Efficacy and safety results from the randomised, placebo-controlled, proof-of-concept PRELUDE study.
    Br J Dermatol. 2024 May 13:ljae181. doi: 10.1093.
    >> Share

  50. ROBINSON J, Kibbi N, Rajan N
    Redefine "benign": A misnomer in the context of patients with genetic skin tumour syndromes.
    Br J Dermatol. 2024 May 10:ljae185. doi: 10.1093.
    >> Share

  51. GUNTHER C
    IL-17 blockade by secukinumab was not effective in controlling lichen planus in a randomized controlled clinical trial.
    Br J Dermatol. 2024 May 8:ljae186. doi: 10.1093.
    >> Share

  52. ZHANG S, Ran M
    Deceptive Pigment Changes in Neoadjuvant Sonidegib Therapy for Basal Cell Carcinoma.
    Br J Dermatol. 2024 May 4:ljae187. doi: 10.1093.
    >> Share

    April 2024
  53. MALLBRIS MJ, Jia B, Zhao Y, Kahlenberg JM, et al
    Concomitant Moderate to Severe Cutaneous Lesions Have Marked Impact on Quality of Life in Patients with Active Systemic Lupus Erythematosus: A Cross-Sectional Insight from Two Phase 3 Randomised Clinical Trials in Adults.
    Br J Dermatol. 2024 Apr 30:ljae183. doi: 10.1093.
    >> Share

  54. HALIOUA B, Skayem C, Merhand S, Ben Hayoun Y, et al
    Long-term consequences on stigmatization and disease burden during adulthood among patients with childhood or adolescence-onset atopic dermatitis.
    Br J Dermatol. 2024 Apr 29:ljae176. doi: 10.1093.
    >> Share

  55. O'REILLY M, Paolino A, Pathmarajah P, Ferguson J, et al
    Dupilumab in Chronic Actinic Dermatitis: a retrospective case series.
    Br J Dermatol. 2024 Apr 24:ljae180. doi: 10.1093.
    >> Share

  56. LI Y, He Y, Yang F, Liang R, et al
    GSDME-mediated keratinocyte pyroptosis participates in the pathogenesis of psoriasis by promoting skin inflammation.
    Br J Dermatol. 2024 Apr 24:ljae179. doi: 10.1093.
    >> Share

  57. NIELSEN JB, Kristiansen IS, Thapa S
    Increasing melanoma incidence with unchanged mortality: more sunshine, better treatment, increased diagnostic activity, overdiagnosis or lowered diagnostic threshold?
    Br J Dermatol. 2024 Apr 24:ljae175. doi: 10.1093.
    >> Share

  58. LEEOLOU MC, Sarin KY, Fiorentino DF
    Filling the Prescription Gap: The Value of Community Support in Psoriasis Management.
    Br J Dermatol. 2024 Apr 18:ljae168. doi: 10.1093.
    >> Share

  59. HUANG D, Zhong X, Jiang Y, Kong L, et al
    Insulin Resistance Impairs Biological Agents Response in Moderate-to-Severe Plaque Psoriasis: Insights from a Prospective Cohort Study in China.
    Br J Dermatol. 2024 Apr 18:ljae147. doi: 10.1093.
    >> Share


  60. The association between vitamin D levels and psoriasis in people aged 40-79 years.
    Br J Dermatol. 2024;190:e54.
    >> Share


  61. Effectiveness and safety of immunoadsorption in the treatment of pemphigus vulgaris and pemphigus foliaceus.
    Br J Dermatol. 2024;190:e53.
    >> Share


  62. Predictors of response to treatment with biologics in people with moderate-to-severe psoriasis.
    Br J Dermatol. 2024;190:e55.
    >> Share


  63. A novel strategy for the treatment of melanoma.
    Br J Dermatol. 2024;190:e51.
    >> Share


  64. Practical guide for epidermolysis bullosa management in the first 4 weeks of life.
    Br J Dermatol. 2024;190:e52.
    >> Share


  65. The Patient Benefit Index for topical treatment (PBI-TOP): a new questionnaire to assess the treatment goals and preferences of people with psoriasis.
    Br J Dermatol. 2024;190:e56.
    >> Share


  66. Deciding on the final set of questions and groups of questions in the Patient-Reported Impact of Dermatological Diseases (PRIDD) tool.
    Br J Dermatol. 2024;190:e57.
    >> Share


  67. Targeting malignant melanoma cells expressing the protein CD20 enhances BRAF-targeted treatment.
    Br J Dermatol. 2024;190:e58.
    >> Share


  68. UK trends in work-related contact dermatitis caused by nickel, chromium and cobalt.
    Br J Dermatol. 2024;190:e59.
    >> Share


  69. 'Gene creams' for genetic diseases?
    Br J Dermatol. 2024;190:e50.
    >> Share

  70. PASSERON T
    A pledge for a better care and consideration of patients with vitiligo.
    Br J Dermatol. 2024;190:614-615.
    >> Share

  71. SAMPOGNA F, Piaserico S
    Deucravacitinib: is there still a place or a need for a new oral agent?
    Br J Dermatol. 2024;190:610-611.
    >> Share

  72. HASAN SB, Bates J, Cannings-John R, Collier F, et al
    Feasibility of daily pain measurement using text messages in hidradenitis suppurativa clinical trials; data from the THESEUS study.
    Br J Dermatol. 2024;190:775-777.
    >> Share

  73. KYUNG S, Woo S, Kim M, Lee H, et al
    Global burden of vaccine-associated alopecia, 1979-2023: a comprehensive analysis of the international pharmacovigilance database.
    Br J Dermatol. 2024;190:764-767.
    >> Share

  74. MOSS C
    Caring for babies born with epidermolysis bullosa.
    Br J Dermatol. 2024;190:608.
    >> Share

  75. RING HC, Thorsen J, Kirby B, Ingram JR, et al
    Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort study.
    Br J Dermatol. 2024;190:769-771.
    >> Share

  76. FAKIH A, Tannous R, Lajnef M, Seneschal J, et al
    Stigma in vitiligo: associated factors and severity strata of the Patient Unique Stigmatization Holistic tool in Dermatology (PUSH-D) score.
    Br J Dermatol. 2024;190:712-717.
    >> Share

  77. HASHIMOTO T, Yamagami J
    Development of a novel treatment for pemphigus and confirmation of its efficacy: a randomized controlled trial of protein A immunoadsorption therapy.
    Br J Dermatol. 2024;190:609.
    >> Share

  78. RIVERA S, Dehner K, Flood A, Dykstra C, et al
    Adverse healthcare experiences are correlated with increased time to diagnosis in women with vulvar inflammatory dermatoses: a retrospective cohort survey.
    Br J Dermatol. 2024;190:761-762.
    >> Share

  79. VAN BEEK N, Eming R, Reuss A, Zillikens D, et al
    Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-Pem Study): a multicentre randomized controlled trial.
    Br J Dermatol. 2024;190:657-667.
    >> Share


  80. The 2024 British Skin Foundation Research Awards are now available.
    Br J Dermatol. 2024;190:778.
    >> Share

  81. CHAIYABUTR C, Dawe R, Lesar A, Ibbotson SH, et al
    A retrospective comparison of early- and late-onset chronic actinic dermatitis: characteristics and management.
    Br J Dermatol. 2024 Apr 16:ljae101. doi: 10.1093.
    >> Share

  82. NASLUND-KOCH C, Skov L
    Shedding light on the smoke: Unraveling the impact of smoking cessation on psoriasis development.
    Br J Dermatol. 2024 Apr 15:ljae163. doi: 10.1093.
    >> Share

  83. PHILLIPS C, Russell E, McNiven A, McPherson T, et al
    A Qualitative Study of the Psychological Morbidity in Paediatric Survivors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
    Br J Dermatol. 2024 Apr 12:ljae154. doi: 10.1093.
    >> Share

  84. BLANCHARD M, Morren MA, Busschots AM, Hauben E, et al
    Paediatric onset lymphomatoid papulosis: results of a multicentre retrospective cohort study, on behalf of the EORTC Cutaneous Lymphoma Tumours Group (CLTG).
    Br J Dermatol. 2024 Apr 10:ljae150. doi: 10.1093.
    >> Share

  85. SIMPSON EL, Eckert L, Gadkari A, Brown TM, et al
    Evaluating the clinical utility of the Atopic Dermatitis Control Tool: measurement properties and agreement between patients' responses and clinicians' impressions of atopic dermatitis control.
    Br J Dermatol. 2024 Apr 9:ljae056. doi: 10.1093.
    >> Share

  86. JONES OT, Matin RN, Walter FM
    Using artificial intelligence-based technologies to support the diagnosis and early detection of melanoma in primary care.
    Br J Dermatol. 2024 Apr 9:ljae094. doi: 10.1093.
    >> Share

  87. CAO Q, Li M
    GLMN variants cause skin hyperpigmentation: a promising potential therapeutic target.
    Br J Dermatol. 2024 Apr 8:ljae149. doi: 10.1093.
    >> Share

  88. ROCCUZZO G, Calvao J, Dobos G, Morsia E, et al
    Cutaneous T-cell lymphoma care across Europe: insights from the Horizon Project.
    Br J Dermatol. 2024 Apr 5:ljae145. doi: 10.1093.
    >> Share

    March 2024
  89. KIM SR, Choi YG, Jo SJ
    Effect of smoking cessation on psoriasis vulgaris, palmoplantar pustulosis, and generalized pustular psoriasis.
    Br J Dermatol. 2024 Mar 27:ljae130. doi: 10.1093.
    >> Share

  90. SANDER N, Stolzl D, Fonfara M, Hartmann J, et al
    Blockade of IL-13 signaling improves skin barrier function and biology in patients with moderate to severe atopic dermatitis.
    Br J Dermatol. 2024 Mar 26:ljae138. doi: 10.1093.
    >> Share

  91. BENTZ P, Weisshaar E
    Biomarkers as key concepts in managing atopic dermatitis and psoriasis: Unlocking new ways of care for patient suffering from chronic hand dermatoses.
    Br J Dermatol. 2024 Mar 26:ljae127. doi: 10.1093.
    >> Share

  92. JOHNSON C, Liao W
    Food for thought: A comment on 'Breast-feeding decreases the risk of developing psoriasis through early adulthood'.
    Br J Dermatol. 2024 Mar 26:ljae135. doi: 10.1093.
    >> Share

  93. SOROKIN AV, Gelfand JM
    New Prospective Cohort Study and Mendelian Randomization Analysis Reveals a Link Between Psoriasis and Cardiovascular Risk Trough Elevated Plasma Triglycerides.
    Br J Dermatol. 2024 Mar 22:ljae129. doi: 10.1093.
    >> Share

  94. TALTY R, Richmond R, Micevic G
    Melanoma TIL therapy commences era of cell-based immunotherapies.
    Br J Dermatol. 2024 Mar 22:ljae126. doi: 10.1093.
    >> Share


  95. Correction to: Circulating biomarkers are associated with disease severity of chronic hand eczema and atopic dermatitis.
    Br J Dermatol. 2024 Mar 22:ljae112. doi: 10.1093.
    >> Share

  96. STRANDMOE AL, Bremer J, Diercks GFH, Gostynski A, et al
    Beyond The Skin: B Cells in Pemphigus Vulgaris, Tolerance and Treatment.
    Br J Dermatol. 2024 Mar 20:ljae107. doi: 10.1093.
    >> Share

  97. JIANG X, Yang C, Wang Z, Liang L, et al
    Loss-of-function variants in GLMN are associated with generalized skin hyperpigmentation with or without glomuvenous malformation.
    Br J Dermatol. 2024 Mar 15:ljae108. doi: 10.1093.
    >> Share


  98. AMBRA1 and loricrin as a test to identify low-risk early-stage melanoma.
    Br J Dermatol. 2024;190:e46.
    >> Share


  99. Blood monitoring during psoriasis treatment with biologics.
    Br J Dermatol. 2024;190:e47.
    >> Share


  100. Safety of bimekizumab over 3 years in patients with psoriasis.
    Br J Dermatol. 2024;190:e38.
    >> Share


  101. International trends in the incidence of cutaneous squamous cell carcinoma and melanoma.
    Br J Dermatol. 2024;190:e40.
    >> Share


  102. Skin barrier dysfunction drives skin inflammation via formylpeptide receptor 1.
    Br J Dermatol. 2024;190:e45.
    >> Share


  103. 2024 British Skin Foundation Small Grants are NOW AVAILABLE.
    Br J Dermatol. 2024;190:603.
    >> Share


  104. Comparison of topical permethrin 5% and benzyl benzoate 25% for treating scabies.
    Br J Dermatol. 2024;190:e39.
    >> Share


  105. Global consensus process to establish a core dataset for hidradenitis suppurativa registries.
    Br J Dermatol. 2024;190:e42.
    >> Share


  106. The relationship between paediatric eczema and cognition.
    Br J Dermatol. 2024;190:e41.
    >> Share


  107. A guide to using the core outcome set for eczema.
    Br J Dermatol. 2024;190:e44.
    >> Share

  108. GARMAN KA, Thoreson N, Strong J, Hallaert P, et al
    Mycophenolate mofetil inhibits Merkel cell carcinoma growth.
    Br J Dermatol. 2024;190:593-595.
    >> Share

  109. CORNMAN HL, Whang KA, Ma E, Aggarwal P, et al
    Severity, impact on quality of life and mental health burden of pruritus in prurigo nodularis: a cross-sectional study of a diverse patient cohort.
    Br J Dermatol. 2024;190:571-572.
    >> Share

  110. CLAIRE FULLER L, Sunderkotter C
    Scabies therapy update: Should 25% benzyl benzoate emulsion be reconsidered as a first-line agent in classical scabies?
    Br J Dermatol. 2024;190:459-460.
    >> Share

  111. NIELSEN W, Drucker AM
    The need and benefit of the Harmonising Outcome Measures for Eczema user's guide.
    Br J Dermatol. 2024;190:462-463.
    >> Share

  112. XIE W, Kong X, Zheng H, Mei H, et al
    Rapid emergence of recalcitrant dermatophytosis caused by a cluster of multidrug-resistant Trichophyton indotineae in China.
    Br J Dermatol. 2024;190:585-587.
    >> Share

  113. NANDA A, Chang YH, Cheng HC, Lai IT, et al
    Autosomal recessive plantar keratoderma with ragged periungual hyperkeratosis caused by a homozygous missense variant in KRT16.
    Br J Dermatol. 2024;190:588-590.
    >> Share

  114. COWPER R
    For itch and insanity.
    Br J Dermatol. 2024;190:568.
    >> Share

  115. BARLOW R, Ahmed A, Fellows J, Goulding J, et al
    Assessing and managing the mental health of people with vitiligo: a UK-wide consultation exercise.
    Br J Dermatol. 2024;190:574-576.
    >> Share

  116. MEYERSBURG D, Hoellwerth M, Brandlmaier M, Handisurya A, et al
    Comparison of topical permethrin 5% vs. benzyl benzoate 25% treatment in scabies: a double-blinded randomized controlled trial.
    Br J Dermatol. 2024;190:486-491.
    >> Share

  117. MOSCARELLA E, Di Brizzi EV, Alpi P, Arcelli A, et al
    Indications for adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma with clear margins: a Delphi consensus.
    Br J Dermatol. 2024;190:578-579.
    >> Share

  118. DONHAUSER T, Gabes M, Ozkan E, Masur C, et al
    What do Hyperhidrosis Quality of Life Index (HidroQoL(c)) scores mean? Transferring science into practice by establishing a score banding system.
    Br J Dermatol. 2024;190:519-526.
    >> Share

  119. WAINMAN HE, Chandran NS, Frew JW, Garg A, et al
    Global consensus process to establish a core dataset for hidradenitis suppurativa registries.
    Br J Dermatol. 2024;190:510-518.
    >> Share

  120. GEORGE CD, Lee T, Hollestein LM, Asgari MM, et al
    Global epidemiology of actinic keratosis in the general population: a systematic review and meta-analysis.
    Br J Dermatol. 2024;190:465-476.
    >> Share

  121. NALDI L, Cassalia F
    Actinic keratosis epidemiology: the good, the bad and the ugly.
    Br J Dermatol. 2024;190:457-458.
    >> Share

  122. OYESIKU L, Dlova N, Ahmed S, Owen DR, et al
    Inclusive and equitable language for skin colour in the British Journal of Dermatology: acknowledging our past and laying the foundations to move forward.
    Br J Dermatol. 2024 Mar 13:ljae064. doi: 10.1093.
    >> Share

  123. AALA WJF, Hou PC, Hong YK, Lin YC, et al
    Dominant dystrophic epidermolysis bullosa is associated with glycolytically active GATA3+ Th2 cells which may contribute to pruritus in lesional skin.
    Br J Dermatol. 2024 Mar 13:ljae110. doi: 10.1093.
    >> Share


  124. Correction to: Malignancy risk in patients with atopic dermatitis: a population-based cohort study.
    Br J Dermatol. 2024 Mar 12:ljae093. doi: 10.1093.
    >> Share

  125. CANTISANI C, Taliano A, Longo C, Bortone G, et al
    Dynamic Optical Coherence Tomography and Reflectance Confocal Microscopy of Basal Cell Carcinoma of the Nipple-Areola Complex.
    Br J Dermatol. 2024 Mar 12:ljae104. doi: 10.1093.
    >> Share

  126. ARMATO U, Dal Pra I
    Discovering skin-rejuvenating matrikines - a basic and applied Dermatology new frontier.
    Br J Dermatol. 2024 Mar 12:ljae100. doi: 10.1093.
    >> Share

  127. CHEN GF, Xu S, White MA, Cohen JM, et al
    Association between atopic dermatitis and eating disorders: a cross-sectional study in the All of Us Research Program.
    Br J Dermatol. 2024 Mar 11:ljae103. doi: 10.1093.
    >> Share

  128. RA AG, Littlewood Z, Barton A, Keevil B, et al
    The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis.
    Br J Dermatol. 2024 Mar 8:ljae096. doi: 10.1093.
    >> Share

  129. REHBINDER EM, Warnberg Gerdin S, Hoyer A, Bradley M, et al
    Frequent oil-baths and skin barrier during infancy in the PreventADALL study.
    Br J Dermatol. 2024 Mar 6:ljae091. doi: 10.1093.
    >> Share

  130. EL HACHEM M, De Marco R, Soria de Francisco JM, Audouze A, et al
    Ichthyosis: multinational European study on patient characteristics and body sites involved with impact on quality of life.
    Br J Dermatol. 2024 Mar 1:ljae082. doi: 10.1093.
    >> Share

    February 2024
  131. RIBERO S, Quaglino P, Roccuzzo G
    Unveiling cutaneous adverse events and prognosis in immunotherapy for melanoma and squamous cell carcinoma.
    Br J Dermatol. 2024 Feb 29:ljae092. doi: 10.1093.
    >> Share

  132. RAMESSUR R, Dand N, Langan SM, Saklatvala J, et al
    Defining disease severity in atopic dermatitis and psoriasis for the application to biomarker research- an inter-disciplinary perspective.
    Br J Dermatol. 2024 Feb 29:ljae080. doi: 10.1093.
    >> Share

  133. GREVE AM, Wulff AB, Bojesen SE, Nordestgaard BG, et al
    Elevated plasma triglycerides increase risk of psoriasis: A cohort and Mendelian randomization study.
    Br J Dermatol. 2024 Feb 27:ljae089. doi: 10.1093.
    >> Share

  134. STAMMLER R, Ta VA, Cohen E, Ram-Wolff C, et al
    Failure of second challenge with Mogamulizumab in CCR4-positive cutaneous T-cell lymphoma.
    Br J Dermatol. 2024 Feb 23:ljae085. doi: 10.1093.
    >> Share

  135. HUGHES O, Thompson AR
    Dealing with Flares in Skin Conditions: How Can We Meet Patient Need?
    Br J Dermatol. 2024 Feb 23:ljae084. doi: 10.1093.
    >> Share


  136. Correction to: How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach.
    Br J Dermatol. 2024 Feb 21:ljae060. doi: 10.1093.
    >> Share

  137. JARIWALA N, Ozols M, Eckersley A, Mambwe B, et al
    Prediction, screening and characterization of novel bioactive tetra-peptide matrikines for skin rejuvenation.
    Br J Dermatol. 2024 Feb 20:ljae061. doi: 10.1093.
    >> Share

  138. GLEESON D, Naveed M, Moorhead L, McAteer H, et al
    Acceptability of 'as needed' biologic therapy in psoriasis: insights from a multi-stakeholder mixed methods study.
    Br J Dermatol. 2024 Feb 17:ljae068. doi: 10.1093.
    >> Share

  139. BABAKINEJAD P, Lapsley R, Forster L, McPherson S, et al
    Cumulative methotrexate dose is not associated with liver fibrosis in patients with a history of moderate to severe psoriasis.
    Br J Dermatol. 2024 Feb 17:ljae069. doi: 10.1093.
    >> Share


  140. Alopecia areata and comorbidities associated with it in Germany.
    Br J Dermatol. 2024;190:e32.
    >> Share


  141. Macrophages dampen skin inflammation after stem cell transplantation.
    Br J Dermatol. 2024;190:e35.
    >> Share


  142. Safety of combination therapy for psoriasis: findings from the BIOBADADERM registry.
    Br J Dermatol. 2024;190:e30.
    >> Share


  143. Comorbidities in people with psoriasis.
    Br J Dermatol. 2024;190:e31.
    >> Share


  144. A clinical trial investigating if antibacterial therapeutic clothing could improve atopic dermatitis.
    Br J Dermatol. 2024;190:e29.
    >> Share


  145. A review of the role of the NLRP1 inflammasome in skin conditions.
    Br J Dermatol. 2024;190:e27.
    >> Share


  146. Greater understanding about the role of a long non-coding RNA in the development of cutaneous squamous cell carcinoma.
    Br J Dermatol. 2024;190:e36.
    >> Share


  147. Results from the Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS).
    Br J Dermatol. 2024;190:e33.
    >> Share


  148. Outcomes that need to be assessed in pyoderma gangrenosum clinical trials.
    Br J Dermatol. 2024;190:e34.
    >> Share

  149. ALABAS OA, Yiu ZZN
    A sprinkle of methotrexate to go with biologics: a safe recipe?
    Br J Dermatol. 2024;190:302-303.
    >> Share

  150. LIU Y, Mo R, Chen Z, Yang Y, et al
    Novel variants in ABCA12 cause erythrokeratodermia variabilis.
    Br J Dermatol. 2024;190:454.
    >> Share

  151. HOPKINS ZH, Chada LMP, Duffin KC
    Defining what matters through core outcomes set development: uniting stakeholder perspectives, empowering patient voices.
    Br J Dermatol. 2024;190:301-302.
    >> Share

  152. BREHON A, Bensefa-Colas L, D'Andrea C, Jeziorski E, et al
    Guidelines for cold urticaria management established by the Centre of Evidence of Dermatology and the Urticaria Group of the French Society of Dermatology.
    Br J Dermatol. 2024;190:445-447.
    >> Share

  153. JACOBSON ME, Rick JW, Gerbens LAA, Baghoomian W, et al
    A core domain set for pyoderma gangrenosum trial outcomes: an international eDelphi and consensus study from the UPGRADE initiative.
    Br J Dermatol. 2024;190:392-401.
    >> Share

  154. KINOSHITA-ISE M
    Updated epidemiology of alopecia areata in Germany: the data tell a lot but hide a lot.
    Br J Dermatol. 2024;190:297-298.
    >> Share

  155. JUNG JM, Cho HS, Kim GH, Won CH, et al
    Psoriasiform mycosis fungoides: a clinical and prognostic retrospective cohort study.
    Br J Dermatol. 2024;190:432-434.
    >> Share

  156. AUGUSTIN M, Ben-Anaya N, Muller K, Hagenstrom K, et al
    Epidemiology of alopecia areata and population-wide comorbidities in Germany: analysis of longitudinal claims data.
    Br J Dermatol. 2024;190:374-381.
    >> Share

  157. INGRAM JR, Bates J, Cannings-John R, Collier F, et al
    Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS): a prospective cohort study.
    Br J Dermatol. 2024;190:382-391.
    >> Share

  158. GARG A, Mastacouris N, Ingram JR, Strunk A, et al
    Addressing high placebo response rates in randomized clinical trials for hidradenitis suppurativa.
    Br J Dermatol. 2024;190:427-429.
    >> Share

  159. VYAS J, Johns JR, Ali FM, Singh RK, et al
    A systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries.
    Br J Dermatol. 2024;190:315-339.
    >> Share

  160. CAI L, Jiang C, Zhang G, Fang H, et al
    A multicenter, randomized, double-blinded, placebo-controlled, phase ? study evaluating the efficacy and safety of Xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis.
    Br J Dermatol. 2024 Feb 15:ljae062. doi: 10.1093.
    >> Share

  161. WAN G, Khattab S, Leung BW, Zhang S, et al
    Cancer Type and Histology Influence Cutaneous Immunotherapy Toxicities: A Multi-Institutional Cohort Study.
    Br J Dermatol. 2024 Feb 15:ljae053. doi: 10.1093.
    >> Share

  162. ZHANG J, Schuttelaar MLA
    How can we better address patients' needs in topical psoriasis treatment?
    Br J Dermatol. 2024 Feb 5:ljae046. doi: 10.1093.
    >> Share

  163. KOBYLETZKI LBV, Svensson A
    Long term outcome measures of atopic dermatitis gain importance: a validation study filling a research gap.
    Br J Dermatol. 2024 Feb 5:ljae049. doi: 10.1093.
    >> Share

  164. EGELER MD, Ryll B
    Survival is not enough: understanding the mental burden of cutaneous melanoma.
    Br J Dermatol. 2024 Feb 3:ljae050. doi: 10.1093.
    >> Share

  165. DAS D, Thimjo J, Lebena A, Guo A, et al
    Breast-feeding decreases the risk of developing psoriasis through early adulthood.
    Br J Dermatol. 2024 Feb 2:ljae043. doi: 10.1093.
    >> Share

  166. WEISS M, Ferre VM, Deschamps L, Evrard D, et al
    Detection of alpha-papillomaviruses in extragenital cutaneous squamous cell carcinomas.
    Br J Dermatol. 2024 Feb 2:ljae047. doi: 10.1093.
    >> Share

    January 2024
  167. MUKHTAR AB, Morgan HJ, Gibbs A, Davies GE, et al
    Targeting CD20-expressing malignant melanoma cells augments BRAF inhibitor killing.
    Br J Dermatol. 2024 Jan 30:ljad502. doi: 10.1093.
    >> Share

  168. DAINTY KN, Thibau IJC, Amog K, Drucker AM, et al
    Towards a patient-centered definition for atopic dermatitis flare: A qualitative study among adults with atopic dermatitis.
    Br J Dermatol. 2024 Jan 30:ljae037. doi: 10.1093.
    >> Share

  169. TRUM NA, Chen L, Zain J, Rosen ST, et al
    Significant survival disparity in Black patients with cutaneous lymphoma: a retrospective cohort study.
    Br J Dermatol. 2024 Jan 29:ljae039. doi: 10.1093.
    >> Share

  170. BERGAMASCHI D
    Improving cancer stem cells killing in malignant melanoma.
    Br J Dermatol. 2024 Jan 29:ljae035. doi: 10.1093.
    >> Share

  171. GROLLEAU C, Walter-Petrich A, Dupin N, Chanal J, et al
    Effectiveness and safety of major systemic treatments in classic and endemic Kaposi sarcoma: a multicenter retrospective study of 110 patients.
    Br J Dermatol. 2024 Jan 25:ljae032. doi: 10.1093.
    >> Share


  172. Hidradenitis suppurativa: a review with new insights into disease mechanisms and potential future treatments.
    Br J Dermatol. 2024;190:e14.
    >> Share


  173. Comparing systemic treatments for eczema.
    Br J Dermatol. 2024;190:e16.
    >> Share


  174. Risk factors for developing a new primary melanoma in people with a melanoma.
    Br J Dermatol. 2024;190:e15.
    >> Share


  175. Targeting Skp2 in blood vessels may be a promising approach to treat psoriasis.
    Br J Dermatol. 2024;190:e22.
    >> Share


  176. A study using machine learning to help identify subgroups of adults with atopic dermatitis.
    Br J Dermatol. 2024;190:e19.
    >> Share


  177. Omalizumab used to treat bullous pemphigoid resistant to other treatments.
    Br J Dermatol. 2024;190:e23.
    >> Share


  178. Genes associated with nodular melanoma.
    Br J Dermatol. 2024;190:e18.
    >> Share


  179. A decreasing trend of atopic dermatitis among children in Sweden.
    Br J Dermatol. 2024;190:e17.
    >> Share


  180. Outcomes that need to be assessed in clinical trials for cutaneous neurofibromas in people with neurofibromatosis type 1.
    Br J Dermatol. 2024;190:e20.
    >> Share

  181. ROMO CG, Sarin KY, Blakeley JO
    Toward risk stratification and personalized therapy for neurofibromas in neurofibromatosis type 1.
    Br J Dermatol. 2024;190:145-146.
    >> Share

  182. KHAN SS, Fuller LC
    Is there a growing global threat of scabies treatment failure? An opportunity to discuss health inequity within UK dermatology.
    Br J Dermatol. 2024;190:139-140.
    >> Share

  183. FAIRLEY JA, Messingham KAN
    Omalizumab therapy of bullous pemphigoid.
    Br J Dermatol. 2024;190:142-143.
    >> Share

  184. KIM EJ, Reusch DB, Anthony H, Schmidt B, et al
    Disseminated juvenile xanthogranulomas with underlying neurotrophic tyrosine receptor kinase fusion and response to larotrectinib.
    Br J Dermatol. 2024;190:283-284.
    >> Share

  185. SOEGIHARTO R, Westmeijer M, Boekema-Bakker N, Groenewegen IAM, et al
    Prevalence of chronic urticaria and healthcare usage of patients with the condition in primary care: a population-based study in the Netherlands.
    Br J Dermatol. 2024;190:287-289.
    >> Share

  186. CEDERLOF M, Jebril W, Larsson H, Curman P, et al
    Individuals with Darier disease have an increased risk of suicide and self-injurious behaviours.
    Br J Dermatol. 2024;190:284-285.
    >> Share

  187. NIELSEN VW, Ring HC, Holgersen N, Thomsen SF, et al
    Elderly male patients with hidradenitis suppurativa have more severe disease independent of disease duration.
    Br J Dermatol. 2024;190:292-293.
    >> Share

  188. WU W, Chen J, Zhu L, Sha Y, et al
    Janus kinase inhibitor for anti-transcription intermediary factor 1-gamma positive cancer-associated dermatomyositis.
    Br J Dermatol. 2024;190:285-287.
    >> Share

  189. KIRTSCHIG G, Singh S
    Interventions for bullous pemphigoid: summary of a Cochrane Review.
    Br J Dermatol. 2024;190:277-279.
    >> Share

  190. FONJUNGO FE, Barnes LA, Cai ZR, Naik HB, et al
    Longitudinal remote monitoring of hidradenitis suppurativa: a pilot study.
    Br J Dermatol. 2024;190:274-276.
    >> Share

  191. KORTE EWH, Spuls PI, van den Akker PC, Kiritsi D, et al
    Harmonization of outcomes in epidermolysis bullosa: report of the Core Outcome Sets for Epidermolysis Bullosa (COSEB) kick-off meeting.
    Br J Dermatol. 2024;190:268-270.
    >> Share

  192. CHEBANI R, Lombart F, Chaby G, Dadban A, et al
    Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients.
    Br J Dermatol. 2024;190:258-265.
    >> Share

  193. KRUEGER JG, Frew J, Jemec GBE, Kimball AB, et al
    Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape.
    Br J Dermatol. 2024;190:149-162.
    >> Share

  194. MBUAGBAW L, Sadeghirad B, Morgan RL, Mertz D, et al
    Failure of scabies treatment: a systematic review and meta-analysis.
    Br J Dermatol. 2024;190:163-173.
    >> Share

  195. PAPACHRISTOU P, Soderholm M, Pallon J, Taloyan M, et al
    Evaluation of an artificial intelligence-based decision support for detection of cutaneous melanoma in primary care - a prospective, real-life, clinical trial.
    Br J Dermatol. 2024 Jan 17:ljae021. doi: 10.1093.
    >> Share

  196. LEBWOHL M, Warren RB, Sofen H, Imafuku S, et al
    Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase 3 poetyk trials.
    Br J Dermatol. 2024 Jan 16:ljae014. doi: 10.1093.
    >> Share

  197. PENA-MARTIN J, Garcia-Ortega MB, Palacios-Ferrer JL, Diaz C, et al
    Identification of novel biomarkers for early diagnosis of malignant melanoma by untargeted LC-HRMS-based metabolomics: a pilot study.
    Br J Dermatol. 2024 Jan 12:ljae013. doi: 10.1093.
    >> Share

  198. BLOME C, Hulswitt L, Meineke A, Augustin M, et al
    Goals and benefits in topical treatment for psoriasis: Development and pilot validation of a patient-reported outcomes tool (PBI-TOP).
    Br J Dermatol. 2024 Jan 12:ljad484. doi: 10.1093.
    >> Share

  199. COCCIMIGLIO M, Chiodo F, van Kooyk Y
    The sialic acid-Siglec immune checkpoint: an opportunity to enhance immune responses and therapy effectiveness in melanoma.
    Br J Dermatol. 2024 Jan 10:ljad517. doi: 10.1093.
    >> Share

  200. KUNGWENGWE G, Gowthorpe C, Ali SR, Warren H, et al
    Prevalence & Odds of Anxiety & Depression in Cutaneous Malignant Melanoma: A Proportional Meta-analysis & Regression.
    Br J Dermatol. 2024 Jan 10:ljae011. doi: 10.1093.
    >> Share

  201. FUNCH AB, Glindvad Ahlstrom M, Johansen JD, Geisler C, et al
    Neutrophil Infiltration in Allergic Contact Dermatitis to Nickel.
    Br J Dermatol. 2024 Jan 4:ljad499. doi: 10.1093.
    >> Share

  202. LI Q, Tsoi LC
    Biologic survival: a novel approach for drug efficacy estimation in psoriasis.
    Br J Dermatol. 2024 Jan 4:ljae007. doi: 10.1093.
    >> Share

  203. YOO LJH, Stefanovic N, Watchorn RE
    Atopic Dermatitis and Autism: Tactile Hypersensitivity Impeding on Topical Therapy Use.
    Br J Dermatol. 2024 Jan 4:ljae005. doi: 10.1093.
    >> Share

  204. SAAD R, Duipmans J, Yerlett N, Plevey K, et al
    Neonatal Epidermolysis Bullosa: a clinical practice guideline.
    Br J Dermatol. 2024 Jan 4:ljae006. doi: 10.1093.
    >> Share

  205. SMITH KA, Hiyoshi A, Vingeliene S, von Kobyletzki L, et al
    Atopic dermatitis and cognitive function: a sibling comparison study among males in Sweden.
    Br J Dermatol. 2024 Jan 3:ljae004. doi: 10.1093.
    >> Share

    December 2023
  206. GURI-LAMCE I, AlRokh Y, Kim Y, Maeshima R, et al
    Topical gene editing therapeutics using lipid nanoparticles: "gene creams" for genetic skin diseases?
    Br J Dermatol. 2023 Dec 27:ljad528. doi: 10.1093.
    >> Share

  207. JOHNSON C, Smith P, Haran K, Kranyak A, et al
    Comment on 'Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study'.
    Br J Dermatol. 2023 Dec 27:ljad529. doi: 10.1093.
    >> Share

  208. JEREMIAN R, Malinowski A, Lytvyn Y, Georgakopoulos JR, et al
    Skin photoaging following sun exposure is associated with decreased epigenetic and biological age and correlates with basal cell carcinoma phenotype.
    Br J Dermatol. 2023 Dec 22:ljad527. doi: 10.1093.
    >> Share


  209. Nemolizumab reduces itch and improves other signs of atopic dermatitis in children aged 6-12 years.
    Br J Dermatol. 2023;190:e2.
    >> Share


  210. A pharmacogenetic study of psoriasis supports the association between a gene (KLK7) and treatment response.
    Br J Dermatol. 2023;190:e8.
    >> Share


  211. Greater understanding about differences in the long-term course of eczema and their risk factors in children.
    Br J Dermatol. 2023;190:e5.
    >> Share


  212. A new method to measure facial depigmentation in vitiligo.
    Br J Dermatol. 2023;190:e7.
    >> Share


  213. A study about how many people around the world have atopic dermatitis.
    Br J Dermatol. 2023;190:e6.
    >> Share


  214. A study looking at a possible new drug, HB0017, for the treatment of psoriasis.
    Br J Dermatol. 2023;190:e3.
    >> Share


  215. Hidradenitis suppurativa in older adults.
    Br J Dermatol. 2023;190:e11.
    >> Share


  216. Genetics and melanoma screening.
    Br J Dermatol. 2023;190:e4.
    >> Share


  217. A short RNA molecule and tumour aggressiveness in people with epidermolysis bullosa.
    Br J Dermatol. 2023;190:e9.
    >> Share


  218. The role of enhancers in eczema and psoriasis.
    Br J Dermatol. 2023;190:e1.
    >> Share

  219. O'SHAUGHNESSY RFL
    Why are squamous cancers so aggressive in recessive dystrophic epidermolysis bullosa? Can we find new therapeutic approaches?
    Br J Dermatol. 2023;190:7-8.
    >> Share

  220. MARQUEZ DG, Sadeghi NB, Westerkam LL, Blum FR, et al
    A survey-based study on experiences with and perspectives toward medical providers among patients with hidradenitis suppurativa.
    Br J Dermatol. 2023;190:127-129.
    >> Share

  221. ELEFTHERIADOU V, Seneschal J
    Assessment of treatment response on facial vitiligo, a step forward. But what about the neck?
    Br J Dermatol. 2023;190:5-6.
    >> Share

  222. SENENT-VALERO M, Matijasevich A, Jara-Rico N, Sivera F, et al
    Drug survival of metformin in patients with hidradenitis suppurativa.
    Br J Dermatol. 2023;190:125-127.
    >> Share

  223. TAN E, Kennedy H, Rademaker M
    When science and evidence is not enough: challenging the recommendations from the Commission on Human Medicines Isotretinoin Expert Working Group.
    Br J Dermatol. 2023;190:116-117.
    >> Share

  224. ILLMER J, Zauner R, Pinon Hofbauer J, Wimmer M, et al
    MicroRNA-200b-mediated reversion of a spectrum of epithelial-to-mesenchymal transition states in recessive dystrophic epidermolysis bullosa squamous cell carcinomas.
    Br J Dermatol. 2023;190:80-93.
    >> Share

  225. BUONTEMPO MG, Sicco KL, Shapiro J
    Comment on 'Treatment of moderate-to-severe alopecia areata with baricitinib in preadolescent children'.
    Br J Dermatol. 2023;190:135.
    >> Share

  226. CHORAGUDI SC, Andrade LF, Yosipovitch G
    Pruritus is associated with longer hospital stays and higher costs in psychiatric inpatients from the USA National Inpatient Sample (2012-2015): a cross-sectional study.
    Br J Dermatol. 2023;190:119-120.
    >> Share

  227. ELEFTHERIADOU V, Hamzavi I, Bae JM, Ezzedine K, et al
    Roadmap to VIRTUAL-GLOBAL: coordinating VItiligo RegisTries for adUlts And chiLdren internationally.
    Br J Dermatol. 2023;190:114-116.
    >> Share

  228. VAN DER WEIJDEN DAY, Koerts NDK, van Munster BC, van der Zee HH, et al
    Hidradenitis suppurativa tarda: defining an understudied elderly population.
    Br J Dermatol. 2023;190:105-113.
    >> Share

  229. MARIN DIT BERTOUD Q, Bertold C, Ezzedine K, Pandya AG, et al
    Reliability and agreement testing of a new automated measurement method to determine facial vitiligo extent using standardized ultraviolet images and a dedicated algorithm.
    Br J Dermatol. 2023;190:62-69.
    >> Share

  230. NARAHARI SR, Aggithaya MG, Ryan TJ, Muralidharan K, et al
    Self-care treatment for lymphoedema of lymphatic filariasis using integrative medicine.
    Br J Dermatol. 2023;190:94-104.
    >> Share

  231. ASFOUR L, Bokhari L, Bhoyrul B, Eisman S, et al
    Comment on 'Treatment of moderate-to-severe alopecia areata with baricitinib in preadolescent children with baricitinib': authors' reply.
    Br J Dermatol. 2023;190:136-137.
    >> Share

  232. TIERNEY E, Evans P, Broderick V, Wynn R, et al
    Successful response to dupilumab in a refractory case of atopic dermatitis-like chronic cutaneous graft-versus-host disease.
    Br J Dermatol. 2023 Dec 20:ljad526. doi: 10.1093.
    >> Share

  233. THOMAS KS, Howells L, Leshem YA, Simpson EL, et al
    How to use the HOME Core Outcome Set for atopic dermatitis trials - a users' guide.
    Br J Dermatol. 2023 Dec 20:ljad497. doi: 10.1093.
    >> Share

  234. FORKEL S, Schubert S, Corvin L, Heine G, et al
    Contact allergies to dental materials in patients.
    Br J Dermatol. 2023 Dec 20:ljad525. doi: 10.1093.
    >> Share

  235. LEFRANCOIS P, Doueidari Z, Kleiner O, Manion R, et al
    Top 10 research priorities for cutaneous squamous cell carcinoma: results of the Skin Investigation Network of Canada Priority Setting Initiative.
    Br J Dermatol. 2023 Dec 19:ljad387. doi: 10.1093.
    >> Share

  236. ABDI P, Haq Z, Diaz MJ, Maibach HI, et al
    Infectious disease among adults with allergic contact dermatitis: A propensity score-matched case-control study.
    Br J Dermatol. 2023 Dec 19:ljad504. doi: 10.1093.
    >> Share

  237. NASLUND-KOCH C, Skov L
    New insights in the complex relationship between psoriasis and vitamin D - and not to forget -obesity!
    Br J Dermatol. 2023 Dec 19:ljad506. doi: 10.1093.
    >> Share

  238. EGGERMONT CJ, Eggermont AMM
    Shifting landscape in skin cancer incidence: the rising tide of cutaneous squamous cell carcinoma and potential implications for prevention.
    Br J Dermatol. 2023 Dec 14:ljad480. doi: 10.1093.
    >> Share

  239. CONTI A, Paolinelli M
    A new approach in monitoring blood tests in anti-TNF-alpha therapies in psoriasis.
    Br J Dermatol. 2023 Dec 13:ljad490. doi: 10.1093.
    >> Share

  240. ORTONNE N
    How to score the impact of treatment on cutaneous neurofibromas in clinical trials?
    Br J Dermatol. 2023 Dec 12:ljad492. doi: 10.1093.
    >> Share

  241. ISKANDAR IYK, Gawkrodger DJ, Gittins M, Byrne L, et al
    Trends in occupational and work-related contact dermatitis attributed to nickel, chromium and cobalt in the UK: findings from The Health and Occupation Research network 1996-2019.
    Br J Dermatol. 2023 Dec 7:ljad488. doi: 10.1093.
    >> Share

  242. THORLACIUS L, Theut Riis P, Musaeus KD, Saunte DM, et al
    Severity rating of specific skin lesions in hidradenitis suppurativa - the patient perspective.
    Br J Dermatol. 2023 Dec 7:ljad491. doi: 10.1093.
    >> Share

  243. SOCKLER PG, Hooper SR, Abuabara K, Ma EZ, et al
    Atopic dermatitis, cognitive function, and psychiatric comorbidities across early childhood and adolescence in a population-based UK birth cohort.
    Br J Dermatol. 2023 Dec 7:ljad486. doi: 10.1093.
    >> Share

  244. ALABAS OA, Mason KJ, Yiu ZZN, Warren RB, et al
    The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Br J Dermatol. 2023 Dec 5:ljad481. doi: 10.1093.
    >> Share

  245. WEIDINGER S, Simpson EL, Silverberg JI, Barbarot S, et al
    Burden of Atopic Dermatitis in Pediatric Patients: An International Cross-sectional Study.
    Br J Dermatol. 2023 Dec 4:ljad449. doi: 10.1093.
    >> Share

  246. BONE M, Inman GJ
    Exon specific oncogenic function of the long non-coding RNA PVT1 in cutaneous squamous cell carcinoma, a promising potential therapeutic target.
    Br J Dermatol. 2023 Dec 1:ljad476. doi: 10.1093.
    >> Share

    November 2023
  247. MOHR C, Li Y, Navsaria LJ, Hinkston CL, et al
    Melanoma risk in skin of color patients with a history of a keratinocyte carcinoma.
    Br J Dermatol. 2023 Nov 30:ljad474. doi: 10.1093.
    >> Share

  248. YU J
    Are perinatal antibiotics responsible for atopic dermatitis? The Debate Rages On.
    Br J Dermatol. 2023 Nov 30:ljad477. doi: 10.1093.
    >> Share

  249. WANG Y, Arbiser JL
    Skp2: A new therapeutic target of psoriasis.
    Br J Dermatol. 2023 Nov 30:ljad479. doi: 10.1093.
    >> Share

  250. KIM M, Choi Y, Lee M, Kang J, et al
    Maternal SARS-CoV-2 infection during pregnancy and subsequent risk of atopic dermatitis in offspring: a nationwide birth cohort study in South Korea.
    Br J Dermatol. 2023 Nov 30:ljad478. doi: 10.1093.
    >> Share

  251. JENSSEN M, Furberg AS, Jorde R, Wilsgaard T, et al
    The association between serum 25-hydroxyvitamin D levels and psoriasis in a large population-based cohort, a cross-sectional analysis of The Tromso Study 2015-16.
    Br J Dermatol. 2023 Nov 28:ljad472. doi: 10.1093.
    >> Share

  252. DOBEL T, Schakel K
    Transcriptional landscape of macrophages in cutaneous graft-versus-host disease.
    Br J Dermatol. 2023 Nov 28:ljad458. doi: 10.1093.
    >> Share

  253. GUENIN S, Andrews E, Lebwohl MG
    Safety and Efficacy of Dual TYK2 Inhibitor and Monoclonal Antibody Therapy for Psoriasis and Psoriatic Arthritis.
    Br J Dermatol. 2023 Nov 27:ljad473. doi: 10.1093.
    >> Share

  254. DAND N, Ramessur R
    New analyses exploring multimorbidity in psoriasis.
    Br J Dermatol. 2023 Nov 27:ljad475. doi: 10.1093.
    >> Share

  255. STROBL J, Gail LM, Krecu L, Madad S, et al
    Diverse macrophage populations contribute to distinct manifestations of human cutaneous graft-versus-host disease.
    Br J Dermatol. 2023 Nov 27:ljad402. doi: 10.1093.
    >> Share

  256. EWEN T, Husain A, Stefanos N, Barrett P, et al
    Validation of Epidermal AMBRA1 and Loricrin (AMBLor) as a prognostic biomarker for non-ulcerated AJCC stage I/II cutaneous melanoma.
    Br J Dermatol. 2023 Nov 25:ljad459. doi: 10.1093.
    >> Share

  257. SHOIMER I, Kleiner O, Manion R, Dutz J, et al
    Top 10 research priorities for basal cell carcinoma: results of the Skin Investigation Network of Canada Priority Setting Initiative.
    Br J Dermatol. 2023 Nov 21:ljad391. doi: 10.1093.
    >> Share

  258. SHAO S, Sun Z, Chu M, Chen J, et al
    FPR1 contributes to epidermal barrier dysfunction-induced skin inflammation through NLRC4-dependent keratinocyte activation.
    Br J Dermatol. 2023 Nov 18:ljad455. doi: 10.1093.
    >> Share

  259. KAMMINGA NCW, Wakkee M, Swart I, Nijsten TEC, et al
    Determining the core content of a digital survivorship care plan for melanoma survivors: A multi-stakeholder Delphi-consensus study.
    Br J Dermatol. 2023 Nov 18:ljad450. doi: 10.1093.
    >> Share

  260. RAJ C, Singh S, Gupta A
    Psychosocial Impact of Severe Autosomal Recessive Congenital Ichthyosis.
    Br J Dermatol. 2023 Nov 17:ljad456. doi: 10.1093.
    >> Share

  261. CAZZANIGA S, Simon D
    Decoding Atopic Dermatitis: Unveiling Phenotypes Through Data-Driven Methods.
    Br J Dermatol. 2023 Nov 17:ljad453. doi: 10.1093.
    >> Share

  262. DESSINIOTI C, Stratigos AJ
    Decoding the nodular melanoma subtype- what about genetics?
    Br J Dermatol. 2023 Nov 17:ljad445. doi: 10.1093.
    >> Share


  263. Survival trends in people with melanoma in Sweden.
    Br J Dermatol. 2023;189:e108.
    >> Share


  264. Improved sleep in adults with atopic dermatitis using the treatment dupilumab.
    Br J Dermatol. 2023;189:e106.
    >> Share


  265. A clinical trial in children and young people with severe eczema comparing methotrexate with ciclosporin.
    Br J Dermatol. 2023;189:e105.
    >> Share


  266. Short anagen hair syndrome is caused by mutations in the WNT10A gene and has a genetic overlap with male pattern hair loss.
    Br J Dermatol. 2023;189:e112.
    >> Share


  267. A roadmap to help with the adoption of core outcome sets in eczema clinical trials.
    Br J Dermatol. 2023;189:e109.
    >> Share


  268. There are early, gradual and late responders for scalp hair regrowth in patients with alopecia areata treated with baricitinib.
    Br J Dermatol. 2023;189:e104.
    >> Share

  269. AHMED A, Eleftheriadou V
    Global VALIANT study: 'lifting the lid' on disappointment and frustration with the lack of effective treatment for vitiligo.
    Br J Dermatol. 2023;189:e99-e102.
    >> Share

  270. STERN RS
    The limitations of persistence as a measure of efficacy of biologic therapies.
    Br J Dermatol. 2023;189:e100-e101.
    >> Share

  271. CESARATO N, Schwieger-Briel A, Gossmann Y, Henne SK, et al
    Short anagen hair syndrome: association with mono- and biallelic variants in WNT10A and a genetic overlap with male pattern hair loss.
    Br J Dermatol. 2023;189:741-749.
    >> Share

  272. REVANKAR RR, Blum F, Yeung H, Patel HA, et al
    Factors influencing patient experience during incision and drainage procedures in hidradenitis suppurativa: an analysis of patient-reported outcomes.
    Br J Dermatol. 2023;189:779-780.
    >> Share

  273. PETRASCA A, Hambly R, Kearney N, Smith CM, et al
    Metformin has anti-inflammatory effects and induces immunometabolic reprogramming via multiple mechanisms in hidradenitis suppurativa.
    Br J Dermatol. 2023;189:730-740.
    >> Share

  274. KUMAR S, Hausen J, Sivalingam S, Humbatova A, et al
    Altered Notch signalling in Dowling-Degos disease: a transcriptomic insight into disease pathogenesis.
    Br J Dermatol. 2023;189:772-774.
    >> Share

  275. YOU Z, Ran Y
    Symmetrical sporotrichosis on the face: pathogen spread from the nose along both sides of facial lymphatic vessels?
    Br J Dermatol. 2023;189:784-785.
    >> Share

  276. SIA T, Webb T, Li S, Moskatel LS, et al
    An exploratory comparative case series of calcitonin gene-related peptide monoclonal antibodies in patients with migraine with rosacea.
    Br J Dermatol. 2023;189:776-778.
    >> Share

  277. LESHEM YA, Simpson EL, Apfelbacher C, Spuls PI, et al
    The Harmonising Outcome Measures for Eczema (HOME) implementation roadmap.
    Br J Dermatol. 2023;189:710-718.
    >> Share

  278. CHERREZ-OJEDA I, Thomsen SF, Gimenez-Arnau A
    Alexithymia prevalence in individuals with chronic urticaria and its association with illness severity and therapeutic profile.
    Br J Dermatol. 2023;189:766-767.
    >> Share

  279. MAGHFOUR J, Dzuali F, Ezekwe N, Gordon J, et al
    Evaluating the efficacy of continuous wave carbon dioxide laser therapy in conjunction with biologics for the management of hidradenitis suppurativa.
    Br J Dermatol. 2023;189:764-783.
    >> Share


  280. Correction to: Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial.
    Br J Dermatol. 2023 Nov 16:ljad442. doi: 10.1093.
    >> Share


  281. The skin has memory: how it works and how to help it forget.
    Br J Dermatol. 2023;189:e103.
    >> Share


  282. A study about the presence of Staphylococcus aureus growth at birth and at 2 months of age in children who developed atopic dermatitis in the first 2 years of life.
    Br J Dermatol. 2023;189:e107.
    >> Share


  283. A non-invasive method using tape stripping for whole-genome skin profiling.
    Br J Dermatol. 2023;189:e113.
    >> Share


  284. The antidiabetic medicine metformin has beneficial effects in hidradenitis suppurativa.
    Br J Dermatol. 2023;189:e111.
    >> Share


  285. Interleukin-17A-expressing mast cells in hidradenitis suppurativa.
    Br J Dermatol. 2023;189:e110.
    >> Share

  286. SACEDON R, de Arriba MC, Martinez-Santamaria L, Maseda R, et al
    Gluten-sensitive enteropathy in recessive dystrophic epidermolysis bullosa.
    Br J Dermatol. 2023;189:774-776.
    >> Share

  287. CHU CB, Yang CC, Hsueh YY, Chen PC, et al
    Aberrant expression of interleukin-17A in mast cells contributes to the pathogenesis of hidradenitis suppurativa.
    Br J Dermatol. 2023;189:719-729.
    >> Share

  288. GIAMARELLOS-BOURBOULIS EJ
    Interleukin-17A derived from mast cells: evidence for an autoinflammatory loop in hidradenitis suppurativa?
    Br J Dermatol. 2023;189:651-652.
    >> Share

  289. ONOUFRIADIS A
    WNT10A gene variants at the root of short anagen hair syndrome.
    Br J Dermatol. 2023;189:653-654.
    >> Share

  290. KING B, Shapiro J, Ohyama M, Egeberg A, et al
    When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials.
    Br J Dermatol. 2023;189:666-673.
    >> Share

  291. MASON KJ, Alabas OA, Dand N, Warren RB, et al
    Characteristics of "Super-Responders" and "Super-Non-Responders" to First Biologic Monotherapy for Psoriasis: A Nested Case-control Study.
    Br J Dermatol. 2023 Nov 11:ljad446. doi: 10.1093.
    >> Share

  292. WAN J
    Changes in the epidemiology of atopic dermatitis: putting them into context.
    Br J Dermatol. 2023 Nov 11:ljad443. doi: 10.1093.
    >> Share

  293. GORDON KB, Langley RG, Warren RB, Okubo Y, et al
    Bimekizumab safety in patients with moderate to severe plaque psoriasis: Pooled data from up to three years of treatment in randomized phase 3 trials.
    Br J Dermatol. 2023 Nov 10:ljad429. doi: 10.1093.
    >> Share

  294. JUNG SY, Han K, Jung JH, Park H, et al
    Cumulative exposure to metabolic syndrome affects the risk of psoriasis differently according to age group: a nationwide cohort study in S. Korea.
    Br J Dermatol. 2023 Nov 9:ljad441. doi: 10.1093.
    >> Share

  295. SHIPMAN WD, Singh K, Cohen JM, Leventhal J, et al
    Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors.
    Br J Dermatol. 2023 Nov 8:ljad342. doi: 10.1093.
    >> Share

  296. SMIT AK, Cust AE
    Unpacking factors contributing to melanoma overdiagnosis: does polygenic risk play a role?
    Br J Dermatol. 2023 Nov 6:ljad431. doi: 10.1093.
    >> Share

  297. YOSIPOVITCH G, Lio PA, Rosmarin D, Serra-Baldrich E, et al
    Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials.
    Br J Dermatol. 2023 Nov 6:ljad435. doi: 10.1093.
    >> Share

  298. RAGAMIN A, Schappin R, de Graaf M, Tupker RA, et al
    The effectiveness of antibacterial therapeutic clothing compared with non-antibacterial therapeutic clothing in patients with moderate-to-severe atopic dermatitis: A randomized controlled, observer-blind pragmatic trial (ABC trial).
    Br J Dermatol. 2023 Nov 4:ljad437. doi: 10.1093.
    >> Share

  299. JUMONVILLE G, Hong D, Khan A, DeWan A, et al
    Digital biobanks are underutilized in dermatology and create opportunities to reduce the burden of skin disease.
    Br J Dermatol. 2023 Nov 4:ljad439. doi: 10.1093.
    >> Share

  300. SHIMON SV, Desai K, Miteva M, Nadji M, et al
    High Expression of Interleukin-17A in Cutaneous Sarcoidosis.
    Br J Dermatol. 2023 Nov 4:ljad438. doi: 10.1093.
    >> Share

  301. DOOLAN BJ, McGrath JA, Mellerio JE
    Beremagene geperpavec (B-VEC) gene therapy for the treatment of cutaneous wounds in patients with dystrophic epidermolysis bullosa: a critical appraisal.
    Br J Dermatol. 2023 Nov 4:ljad433. doi: 10.1093.
    >> Share

  302. HAIDER S, Granell R, Curtin JA, Holloway JW, et al
    Identification of eczema clusters and their association with filaggrin and atopic comorbidities: analysis of five birth cohorts.
    Br J Dermatol. 2023 Nov 3:ljad326. doi: 10.1093.
    >> Share

  303. MELNIK BC
    Metformin attenuates mechanistic target of rapamycin complex 1/hypoxia-inducible factor-1alpha-driven glycolysis reducing keratinocyte and T helper 17 cell proliferation in hyperproliferative inflammatory skin diseases.
    Br J Dermatol. 2023 Nov 2:ljad362. doi: 10.1093.
    >> Share

  304. LI C, Sun C, Mahapatra KD, Riihila P, et al
    Long non-coding RNA PVT1 is overexpressed in cutaneous squamous cell carcinoma and exon 2 is critical for its oncogenicity.
    Br J Dermatol. 2023 Nov 1:ljad419. doi: 10.1093.
    >> Share

    October 2023
  305. KAWSAR A, Hussain K, Fearfield L
    How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach.
    Br J Dermatol. 2023;189.
    >> Share

  306. HUGHES O, Bewley A
    Is it really ever 'just acne'? Considering the psychodermatology of acne.
    Br J Dermatol. 2023;189.
    >> Share

  307. AHMED A, Fearfield L, Griffiths TW
    Resilience in skin disease.
    Br J Dermatol. 2023;189.
    >> Share

  308. GRIFFITHS TW, Watson REB, Langton AK
    Skin ageing and topical rejuvenation strategies.
    Br J Dermatol. 2023;189.
    >> Share

  309. CHIESA FUXENCH Z, Mitra N, Del Pozo D, Hoffstad O, et al
    In utero or early in life exposure to antibiotics and the risk of childhood atopic dermatitis, a population-based cohort study.
    Br J Dermatol. 2023 Oct 28:ljad428. doi: 10.1093.
    >> Share

  310. OLSEN CM, Pandeya N, Ragaini BS, Neale RE, et al
    International patterns and trends in the incidence of melanoma and cutaneous squamous cell carcinoma, 1989-2020.
    Br J Dermatol. 2023 Oct 27:ljad425. doi: 10.1093.
    >> Share

  311. CALABRESE L, Fiocco Z, Mellett M, Aoki R, et al
    The Role of NLRP1 Inflammasome in Skin Cancer and Inflammatory Skin Diseases.
    Br J Dermatol. 2023 Oct 27:ljad421. doi: 10.1093.
    >> Share


  312. Multiple skin lesions, especially on the legs, predict a poorer prognosis in skin lymphoma with large tumour cells.
    Br J Dermatol. 2023;189:e98.
    >> Share


  313. Lifetime burden of Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Br J Dermatol. 2023;189:e92.
    >> Share


  314. Safety and effectiveness of amlitelimab, a potential new treatment for atopic dermatitis: results of a clinical trial.
    Br J Dermatol. 2023;189:e90.
    >> Share


  315. The effect of extracorporeal photopheresis on cytokines released by leukaemic cutaneous T-cell lymphoma.
    Br J Dermatol. 2023;189:e97.
    >> Share


  316. Views on vitiligo disease course and treatment among people living with vitiligo and healthcare providers worldwide.
    Br J Dermatol. 2023;189:e94.
    >> Share


  317. Understanding the biology of cutaneous squamous cell carcinoma.
    Br J Dermatol. 2023;189:e96.
    >> Share


  318. Comparison of biologic treatments in psoriasis using treatment duration.
    Br J Dermatol. 2023;189:e93.
    >> Share


  319. Greater understanding about interpreting the Recap of atopic eczema (RECAP) questionnaire.
    Br J Dermatol. 2023;189:e95.
    >> Share


  320. Comparison of risankizumab with apremilast for the treatment of moderate psoriasis.
    Br J Dermatol. 2023;189:e91.
    >> Share

  321. OFENLOCH RF
    Filling the gap: investigating the interpretability of the Recap of atopic eczema questionnaire.
    Br J Dermatol. 2023;189:506-507.
    >> Share

  322. SUH-YUN JOH C, Jeong S, Lee C, Lee HJ, et al
    Spatial transcriptomic profiling reveals the pathophysiology of early-stage hidradenitis suppurativa.
    Br J Dermatol. 2023;189:643-645.
    >> Share

  323. KUMAR N, Pourang A, Ezekwe N, Parks-Miller A, et al
    A method for assessing rater reliability in applying the Vitiligo Area Scoring Index.
    Br J Dermatol. 2023;189:645-647.
    >> Share

  324. CHENG Q, Yang F, Xue R, Wang H, et al
    Postzygotic gain-of-function variants in FGFR2 in two patients with hair follicle naevus.
    Br J Dermatol. 2023;189:641-643.
    >> Share

  325. SHIELDS A, Barbieri JS
    Effectiveness of spironolactone for women with acne vulgaris (SAFA) trial: a critically appraised topic.
    Br J Dermatol. 2023;189:509-510.
    >> Share

  326. HAMZAVI IH, Bibeau K, Grimes P, Harris JE, et al
    Exploring the natural and treatment history of vitiligo: perceptions of patients and healthcare professionals from the global VALIANT study.
    Br J Dermatol. 2023;189:569-577.
    >> Share

  327. INGEN-HOUSZ-ORO S
    Epidermal necrolysis: a chronic disease associated with loss-of-life expectancy and lifetime healthcare expenditure.
    Br J Dermatol. 2023;189:505-506.
    >> Share

  328. LIU Y, Li Q, Chu C, Zhou Y, et al
    Insights into Stevens-Johnson syndrome/toxic epidermal necrolysis lifetime burden: assessing life expectancy, healthcare costs and quality of life.
    Br J Dermatol. 2023;189:648.
    >> Share

  329. ZHANG J, Ragamin A, Romeijn GLE, Loman L, et al
    Validity, reliability, responsiveness and interpretability of the Recap of atopic eczema (RECAP) questionnaire.
    Br J Dermatol. 2023;189:578-587.
    >> Share

  330. CHEN GF, Shaw KS, Sanchez-Melendez S, Vleugels RA, et al
    Increased risk of depression in patients with discoid lupus erythematosus: a nested, case-control study in the All of Us Research Program.
    Br J Dermatol. 2023;189:628-629.
    >> Share

  331. WELFRINGER-MORIN A, Bataille P, Drummond D, Bellon N, et al
    Comparison of idiopathic and drug-induced epidermal necrolysis in children.
    Br J Dermatol. 2023;189:631-633.
    >> Share

  332. LI D, Technau-Hafsi K, Giehl K, Hoeger PH, et al
    Targeted anti-interleukin-17 therapy for linear porokeratosis.
    Br J Dermatol. 2023;189:630-631.
    >> Share

  333. SOW Y, Salame N, Siira MR, Flowers N, et al
    Healthcare experiences among patients with hidradenitis suppurativa: a qualitative study.
    Br J Dermatol. 2023;189:624-626.
    >> Share

  334. FERTITTA L, Bergqvist C, Sarin K, Plotkin SR, et al
    A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials.
    Br J Dermatol. 2023 Oct 25:ljad397. doi: 10.1093.
    >> Share

  335. CHALITSIOS CV, Meena D, Manou M, Papagiannopoulos C, et al
    Multiple long-term conditions in people with psoriasis: a latent class and bidirectional Mendelian randomisation analysis.
    Br J Dermatol. 2023 Oct 24:ljad410. doi: 10.1093.
    >> Share

  336. BERGERON A, Nessim C, Kleiner O, Manion R, et al
    SkIN Canada Priority Setting Initiative ranks the Top Ten evidence uncertainties for Merkel cell carcinoma.
    Br J Dermatol. 2023 Oct 21:ljad398. doi: 10.1093.
    >> Share

  337. VALLEEKANTHAN M, Cree H
    Challenges in adult services for a young adult with a rare skin disease.
    Br J Dermatol. 2023 Oct 21:ljad403. doi: 10.1093.
    >> Share

  338. NYMAND L, Nielsen ML, Vittrup I, Halling AS, et al
    Atopic dermatitis phenotypes based on cluster analysis of the Danish Skin Cohort.
    Br J Dermatol. 2023 Oct 18:ljad401. doi: 10.1093.
    >> Share

  339. XIE X, Cui Q, Jiang T, Zhao Z, et al
    A Critical Role of Endothelial Skp2/PTEN Axis in Angiogenesis and Psoriasis.
    Br J Dermatol. 2023 Oct 18:ljad399. doi: 10.1093.
    >> Share

  340. LLUCH-GALCERA JJ, Carrascosa JM, Gonzalez-Quesada A, Rivera-Diaz R, et al
    Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry.
    Br J Dermatol. 2023 Oct 17:ljad382. doi: 10.1093.
    >> Share

  341. DRUCKER AM, Lam M, Elsawi R, Prieto-Merino D, et al
    Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis.
    Br J Dermatol. 2023 Oct 13:ljad393. doi: 10.1093.
    >> Share

  342. COLVIN A, Petukhova L
    Who has skin in the game? Expanding patient opportunities for research engagement is a win-win for dermatology.
    Br J Dermatol. 2023 Oct 13:ljad394. doi: 10.1093.
    >> Share

  343. BERGQVIST C
    Is there room for another Anti-IL-17 in the Crowded Psoriasis Therapeutic Landscape?
    Br J Dermatol. 2023 Oct 12:ljad383. doi: 10.1093.
    >> Share

  344. MURPHY MJ, Hwang E, Singh K, Lee T, et al
    Machine learning analysis of pre-treatment skin biopsies predicts non-response to dupilumab in patients with eczematous dermatitis.
    Br J Dermatol. 2023 Oct 11:ljad389. doi: 10.1093.
    >> Share

  345. HAUGAARD JH, Thein D, Egeberg A
    Characteristics and Prognosis in First-Time Hospitalized Generalized Pustular Psoriasis Patients: Insights from National Databases.
    Br J Dermatol. 2023 Oct 7:ljad384. doi: 10.1093.
    >> Share

  346. AUTIER P
    Melanoma incidence and COVID-19 lockdowns in the Netherlands.
    Br J Dermatol. 2023 Oct 4:ljad376. doi: 10.1093.
    >> Share

    September 2023
  347. AF KLINTEBERG M, Winberg A, Andersson M, Ronmark E, et al
    Decreasing prevalence of atopic dermatitis among Swedish schoolchildren. Three repeated population-based surveys.
    Br J Dermatol. 2023 Sep 30:ljad370. doi: 10.1093.
    >> Share

  348. REYNAUD B, Jacquemus J, Chabaud S, Ouldbey Y, et al
    Benefit of skin surgical revision in high-risk basal cell carcinoma according to histopathological margins.
    Br J Dermatol. 2023 Sep 28:ljad372. doi: 10.1093.
    >> Share

  349. STARK MS, Sturm RA, Pan Y, Smit DJ, et al
    Assessing the genetic risk of nodular melanoma using a candidate gene approach.
    Br J Dermatol. 2023 Sep 28:ljad365. doi: 10.1093.
    >> Share

  350. SAKAI A, Shinkuma S, Miura N, Deguchi T, et al
    Possible relation of cathepsin C activity and seasonal fluctuation of skin lesions in Papillon-Lefevre syndrome.
    Br J Dermatol. 2023 Sep 27:ljad373. doi: 10.1093.
    >> Share


  351. Correction to: TMEM232 promotes the inflammatory response in atopic dermatitis via the nuclear factor-kappaB and signal transducer and activator of transcription 3 signalling pathways.
    Br J Dermatol. 2023 Sep 23:ljad346. doi: 10.1093.
    >> Share


  352. Correction to: Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study.
    Br J Dermatol. 2023 Sep 23:ljad340. doi: 10.1093.
    >> Share

  353. SMITH CH, Yiu ZZN, Bale T, Burden AD, et al
    British Association of Dermatologists guidelines for biologic therapy for psoriasis 2023 - a pragmatic update.
    Br J Dermatol. 2023 Sep 22:ljad347. doi: 10.1093.
    >> Share

  354. TOLAND AE
    Expanding the feasibility of large genomics skin studies using epidermal DNA collected via tape-stripping.
    Br J Dermatol. 2023 Sep 22:ljad360. doi: 10.1093.
    >> Share

  355. FLOHR C, Rosala-Hallas A, Jones AP, Beattie P, et al
    Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre, parallel group, assessor-blinded clinical trial.
    Br J Dermatol. 2023 Sep 19:ljad281. doi: 10.1093.
    >> Share


  356. The risk of deep-vein blood clots in people with atopic dermatitis (eczema).
    Br J Dermatol. 2023;189:e75.
    >> Share


  357. A review of major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors.
    Br J Dermatol. 2023;189:e69.
    >> Share


  358. Gaining a better understanding of the causes of hidradenitis suppurativa.
    Br J Dermatol. 2023;189:e77.
    >> Share


  359. Clinical trial results for treatment of psoriasis with izokibep.
    Br J Dermatol. 2023;189:e70.
    >> Share


  360. How common is generalized pustular psoriasis in Malaysia?
    Br J Dermatol. 2023;189:e73.
    >> Share


  361. Once-daily roflumilast foam for treating scalp and body psoriasis.
    Br J Dermatol. 2023;189:e71.
    >> Share


  362. Eleven recommendations to support mental health in children and young people with skin conditions.
    Br J Dermatol. 2023;189:e78.
    >> Share

  363. HERBERT S, Haughton R, Liakos W, Wang J, et al
    A qualitative exploration of patient experiences in pyoderma gangrenosum.
    Br J Dermatol. 2023;189:496-498.
    >> Share

  364. SUHRKAMP I, Gerdes S
    The interleukin-1 pathway as a treatment target in early-stage hidradenitis suppurativa?
    Br J Dermatol. 2023;189:365-366.
    >> Share

  365. MARONESE CA, Ingram JR, Marzano AV
    Has the time come to assess small-molecule/biologic drug combinations for the management of moderate-to-severe hidradenitis suppurativa?
    Br J Dermatol. 2023;189:467-468.
    >> Share

  366. CHANDLER DJ, Yamamoto R, Hay RJ
    Use of direct microscopy to diagnose superficial mycoses: a survey of UK dermatology practice.
    Br J Dermatol. 2023;189:480-481.
    >> Share

  367. ORTNER VK, Zibert JR, Manole I, Mondragon AC, et al
    Agreement and reliability of remote assessment of actinic keratosis: a proof-of-concept study using smartphone photographs.
    Br J Dermatol. 2023;189:474-475.
    >> Share

  368. BRANS R
    Promising results for treatment of severe chronic hand eczema with dupilumab.
    Br J Dermatol. 2023;189:360-361.
    >> Share

  369. HARMAN KE, Barha J, Chalmers JR, Dart JKG, et al
    The top 10 research priorities for the treatment of bullous pemphigoid, mucous membrane pemphigoid and pemphigus vulgaris in the UK: results of a James Lind Alliance Priority Setting Partnership.
    Br J Dermatol. 2023;189:469-498.
    >> Share

  370. VOORBERG AN, Kamphuis E, Christoffers WA, Schuttelaar MLA, et al
    Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study.
    Br J Dermatol. 2023;189:400-409.
    >> Share

  371. VAN DOORN R
    Multiple Primary Melanoma: Risk Factors Reviewed.
    Br J Dermatol. 2023 Sep 15:ljad343. doi: 10.1093.
    >> Share

  372. NAKAHARA T, Fujita H, Tajima Y, Arima K, et al
    Evaluating the usefulness of the Atopic Dermatitis Control Tool for assessing disease control among individuals with atopic dermatitis in Japan.
    Br J Dermatol. 2023 Sep 15:ljad344. doi: 10.1093.
    >> Share


  373. Patient assessment of psoriasis severity.
    Br J Dermatol. 2023;189:e76.
    >> Share


  374. Features of very thin melanoma that predict lymph node involvement.
    Br J Dermatol. 2023;189:e74.
    >> Share


  375. Correction to: Partner bereavement and risk of psoriasis and atopic eczema: cohort studies in the U.K. and Denmark, and to: Partner bereavement and risk of chronic urticaria, alopecia areata and vitiligo: cohort studies in the UK and Denmark.
    Br J Dermatol. 2023 Sep 14:ljad338. doi: 10.1093.
    >> Share

  376. TIAN J, Zhang D, Yang Y, Huang Y, et al
    The global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study.
    Br J Dermatol. 2023 Sep 14:ljad339. doi: 10.1093.
    >> Share

  377. GUERRERO-JUAREZ CF, Goyal PK, Amber KT
    Targeting IL-4/IL-13 in immune checkpoint inhibitor induced bullous pemphigoid: a cautionary note on the beneficial effect of Th2 in melanoma and immunotherapy.
    Br J Dermatol. 2023 Sep 13:ljad324. doi: 10.1093.
    >> Share

  378. GERDES S, Staubach P, Dirschka T, Wetzel D, et al
    Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment.
    Br J Dermatol. 2023 Sep 12:ljad186. doi: 10.1093.
    >> Share

  379. PANDEYA N, Dusingize JC, Olsen CM, MacGregor S, et al
    Does genetic risk modify the effect of skin screening on melanoma detection rates?
    Br J Dermatol. 2023 Sep 8:ljad333. doi: 10.1093.
    >> Share

  380. VEYSEY E
    Risankizumab vs. apremilast in the era of skin clearance.
    Br J Dermatol. 2023 Sep 6:ljad328. doi: 10.1093.
    >> Share

  381. ZHANG H, Patrick MT, Tejasvi T, Sarkar MK, et al
    Retrospective pharmacogenetic study of psoriasis highlights the role of KLK7 in TNF signaling.
    Br J Dermatol. 2023 Sep 6:ljad332. doi: 10.1093.
    >> Share

  382. FUXENCH ZCC, Wan J, Wang S, Syed MN, et al
    Atopic Dermatitis and risk for headache disorders and migraines: a population-based cohort study in children and adults from the United Kingdom.
    Br J Dermatol. 2023 Sep 6:ljad325. doi: 10.1093.
    >> Share

  383. NGUYEN V, Gao C, Hochman ML, Kravitz J, et al
    Endothelial cells differentiated from patient dermal fibroblast-derived induced pluripotent stem cells resemble vascular malformations of Port Wine Birthmark.
    Br J Dermatol. 2023 Sep 6:ljad330. doi: 10.1093.
    >> Share

  384. JIANG C, Du Y, Liu X, Wang J, et al
    Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody targeting IL-17A, in healthy subjects and patients with moderate to severe plaque psoriasis (PsO).
    Br J Dermatol. 2023 Sep 5:ljad315. doi: 10.1093.
    >> Share

  385. RIDDLE AO, Jambusaria-Pahlajani A
    Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients: A Critically-appraised Research Paper.
    Br J Dermatol. 2023 Sep 4:ljad318. doi: 10.1093.
    >> Share

  386. LLOYD-LAVERY A
    Nemolizumab to target the itch-scratch cycle in paediatric atopic dermatitis.
    Br J Dermatol. 2023 Sep 2:ljad319. doi: 10.1093.
    >> Share

  387. BANILA C, Green D, Katsanos D, Viana J, et al
    A non-invasive method for whole genome skin methylome profiling.
    Br J Dermatol. 2023 Sep 2:ljad316. doi: 10.1093.
    >> Share

  388. SUI JY, Eichenfield DZ, Sun BK
    The Role of Enhancers in Psoriasis and Atopic Dermatitis.
    Br J Dermatol. 2023 Sep 2:ljad321. doi: 10.1093.
    >> Share

  389. LEE EY, Drucker AM
    A detailed evaluation of dupilumab's effect on sleep in adults with atopic dermatitis.
    Br J Dermatol. 2023 Sep 2:ljad320. doi: 10.1093.
    >> Share

  390. WEINER D, Ly A, Talluru S, Munjal A, et al
    Efficacy of single-agent chemotherapy with pegylated liposomal doxorubicin or gemcitabine in a diverse cohort of patients with recalcitrant cutaneous T-cell lymphoma.
    Br J Dermatol. 2023 Sep 1:ljad311. doi: 10.1093.
    >> Share

    August 2023
  391. HTET KZ, Griffiths CEM, Lwin SM
    Essential Emergency Skincare: A Global Health Dermatology Innovation for Myanmar and Beyond.
    Br J Dermatol. 2023 Aug 25:ljad302. doi: 10.1093.
    >> Share

  392. ELEFTHERIADOU V, Thompson AR
    Skin is a window to one's inner world.
    Br J Dermatol. 2023 Aug 25:ljad300. doi: 10.1093.
    >> Share


  393. Correction to: Validation of a microRNA liquid biopsy assay for diagnosis and risk stratification of invasive cutaneous melanoma.
    Br J Dermatol. 2023 Aug 24:ljad288. doi: 10.1093.
    >> Share


  394. Validation of a blood test for melanoma.
    Br J Dermatol. 2023;189:e65.
    >> Share


  395. The impact of a dose reduction of dupilumab when treating people with well-controlled atopic dermatitis.
    Br J Dermatol. 2023;189:e68.
    >> Share


  396. Comparison of treatment for psoriasis with methotrexate and adalimumab.
    Br J Dermatol. 2023;189:e64.
    >> Share

  397. CLAESON M
    Real-world data show improved melanoma survival in Sweden.
    Br J Dermatol. 2023 Aug 24:ljad309. doi: 10.1093.
    >> Share


  398. Greater understanding about the impact of house dust mites in vitiligo.
    Br J Dermatol. 2023;189:e67.
    >> Share

  399. NG WHS, Smith SD
    New considerations and implications with weekly patient-reported symptom monitoring and eczema severity.
    Br J Dermatol. 2023;189:e58-e59.
    >> Share

  400. PICARDO M
    Vitiligo and keratinocytes or keratinocytes and vitiligo?
    Br J Dermatol. 2023;189:257.
    >> Share

  401. KEARNEY N, Kirby B
    Moving toward structured, specialized hidradenitis suppurativa care to improve patient outcomes.
    Br J Dermatol. 2023;189:e57-e58.
    >> Share

  402. ROESNER LM, Wittmann M
    Hand eczema leaves systemic traces.
    Br J Dermatol. 2023;189:e56-e59.
    >> Share

  403. MALOVITSKI K, Sarig O, Feller Y, Bergson S, et al
    Defective cathepsin Z affects EGFR expression and causes autosomal dominant palmoplantar keratoderma.
    Br J Dermatol. 2023;189:302-311.
    >> Share

  404. WILLIAMS JC, Alhusayen R, Guilbault S, Ingram JR, et al
    Patient-reported influences on COVID-19 vaccine acceptance and hesitancy in people with hidradenitis suppurativa.
    Br J Dermatol. 2023;189:351-353.
    >> Share

  405. LEIGHTON P, Howells L, Bates J, Gibbons A, et al
    Research priorities in the management of hidradenitis suppurativa.
    Br J Dermatol. 2023;189:343-345.
    >> Share

  406. BELLEFEUILLE G, Paiewonsky B, Khalid B, Freese RL, et al
    Worst area local Hidradenitis suppurativa Activity and Severity Index-Revised (W-HASI-R): a study evaluating construct validity.
    Br J Dermatol. 2023;189:338-354.
    >> Share

  407. SHIPMAN WD, Singh K, Cohen JM, Leventhal J, et al
    Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment.
    Br J Dermatol. 2023;189:339-341.
    >> Share

  408. PHAM JP, Wark KJL, Woods J, Frew JW, et al
    Resident cutaneous memory T-cells: A clinical review of their role in chronic inflammatory dermatoses and potential as therapeutic targets.
    Br J Dermatol. 2023 Aug 21:ljad303. doi: 10.1093.
    >> Share

  409. THOMAS SE, van den Reek JMPA, Seyger MMB, de Jong EMGJ, et al
    How to define a 'super-responder' to biologics in psoriasis studies?
    Br J Dermatol. 2023 Aug 18:ljad280. doi: 10.1093.
    >> Share

  410. SONG B, Wu C, Liu W, Wang Y, et al
    Integrative serum proteomics analysis reveals distinct immune and cardiovascular profiles dysregulation in erythrodermic psoriasis.
    Br J Dermatol. 2023 Aug 16:ljad283. doi: 10.1093.
    >> Share

  411. ARENTS BWM, van Zuuren EJ, Hughes O, Fedorowicz Z, et al
    The future is now: the Global Atopic Dermatitis Atlas (GADA).
    Br J Dermatol. 2023 Aug 11:ljad286. doi: 10.1093.
    >> Share

  412. SMITH J, Cust AE, Lo SN
    Risk factors for subsequent primary melanoma for patients with previous melanoma: A systematic review and meta-analysis.
    Br J Dermatol. 2023 Aug 10:ljad275. doi: 10.1093.
    >> Share

  413. MEROLA JF, Chiou AS, During E, Costanzo A, et al
    Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase 4 randomized double-blinded placebo-controlled DUPISTAD study.
    Br J Dermatol. 2023 Aug 10:ljad284. doi: 10.1093.
    >> Share

  414. MIYAGAKI T, Inoue N, Kamijo H, Boki H, et al
    Prognostic factors for primary cutaneous anaplastic large cell lymphoma: a multicenter retrospective study from Japan.
    Br J Dermatol. 2023 Aug 4:ljad266. doi: 10.1093.
    >> Share

    July 2023
  415. IGARASHI A, Katsunuma T, Matsumura T, Komazaki H, et al
    Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: Results from a phase III, randomised, double-blind, placebo-controlled, multicentre study.
    Br J Dermatol. 2023 Jul 31:ljad268. doi: 10.1093.
    >> Share

  416. PAN CX, Kim DY, Lau CB, Lau WC, et al
    Comparative analysis of immune-related adverse events among patients with melanoma on immune checkpoint inhibitors: A retrospective cohort study.
    Br J Dermatol. 2023 Jul 28:ljad271. doi: 10.1093.
    >> Share

  417. CHULAROJANAMONTRI L, Panjapakkul W, Chaiyabutr C, Pruksaeakanan C, et al
    Blood-based Scoring Systems for Identifying Significant Liver Fibrosis in Psoriasis Patients.
    Br J Dermatol. 2023 Jul 28:ljad269. doi: 10.1093.
    >> Share

  418. STEIN GOLD LF, Bagel J, Tyring SK, Hong HC, et al
    Comparison of risankizumab and apremilast for the treatment of adult patients with moderate plaque psoriasis eligible for systemic therapy: results from a randomised, open-label, assessor-blinded phase IV (IMMpulse) study.
    Br J Dermatol. 2023 Jul 25:ljad252. doi: 10.1093.
    >> Share

  419. PILERI A, Pimpinelli N
    The role of the immune system in cutaneous T-cell lymphoma, an area requiring more investigation.
    Br J Dermatol. 2023 Jul 24:ljad255. doi: 10.1093.
    >> Share

  420. RINNOV MR, Gerner T, Halling AS, Liljendahl MS, et al
    The association between S. aureus colonization on cheek skin at 2 months and subsequent atopic dermatitis in a prospective birth cohort.
    Br J Dermatol. 2023 Jul 22:ljad249. doi: 10.1093.
    >> Share

  421. MARCOMBES C, Penso L, Weill A, Dray-Spira R, et al
    Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS).
    Br J Dermatol. 2023 Jul 21:ljad248. doi: 10.1093.
    >> Share

  422. MICEVIC G, Daniels A, Flavell RA
    New insights into PD-1 blockade associated cutaneous immune-related adverse events.
    Br J Dermatol. 2023 Jul 20:ljad236. doi: 10.1093.
    >> Share

  423. THAI AA, Young RJ, Bressel M, Angel C, et al
    Comprehensive profiling identifies tumour and immune-microenvironmental differences in clinical subsets of cutaneous squamous cell carcinoma.
    Br J Dermatol. 2023 Jul 20:ljad250. doi: 10.1093.
    >> Share

  424. FAVARO R, Formai A, Pavia G, Gargiulo L, et al
    The impact of biologic therapy for moderate-to-severe psoriasis on the immune responses to SARS-CoV2 infection and vaccination.
    Br J Dermatol. 2023 Jul 18:ljad242. doi: 10.1093.
    >> Share

  425. WEIDINGER S, Bieber T, Cork MJ, Reich A, et al
    Safety and efficacy of amlitelimab, a fully human, non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomised placebo-controlled trial.
    Br J Dermatol. 2023 Jul 18:ljad240. doi: 10.1093.
    >> Share

  426. SMAK GREGOOR AM, van Egmond S, Nijsten TEC, Wakkee M, et al
    Time to reconsider skin cancer related follow-up visits.
    Br J Dermatol. 2023 Jul 18:ljad241. doi: 10.1093.
    >> Share

  427. VIKSTROM S, Mikiver R, Lapins J, Nielsen K, et al
    Increasing melanoma incidence and survival trend shifts with improved melanoma-specific survival between 1990 and 2020 in Sweden.
    Br J Dermatol. 2023 Jul 18:ljad244. doi: 10.1093.
    >> Share


  428. Benefits of treatment with dupilumab for children aged 6-11 years with severe atopic dermatitis.
    Br J Dermatol. 2023;189:e39.
    >> Share


  429. The impact of weekly eczema symptom assessments on patient outcomes.
    Br J Dermatol. 2023;189:e38.
    >> Share


  430. Imsidolimab for the treatment of generalized pustular psoriasis.
    Br J Dermatol. 2023;189:e37.
    >> Share


  431. A review of genetic hair disorders.
    Br J Dermatol. 2023;189:e36.
    >> Share

  432. LOFVENDAHL S, Norlin JM, Schmitt-Egenolf M
    Comorbidities in palmoplantar pustulosis: a Swedish population-based register study.
    Br J Dermatol. 2023;189:230-232.
    >> Share

  433. BAKER A, Mitchell EJ, Partlett C, Thomas KS, et al
    Evaluating the effect of weekly patient-reported symptom monitoring on trial outcomes: results of the Eczema Monitoring Online randomized controlled trial.
    Br J Dermatol. 2023;189:180-187.
    >> Share

  434. MOGHADAM P, Tancrede E, Bouaziz JD, Kallout J, et al
    Efficacy and safety of dupilumab in bullous pemphigoid: a retrospective multicentric study of 36 patients.
    Br J Dermatol. 2023;189:244-246.
    >> Share

  435. SCHULTHEIS M, Staubach P, Nikolakis G, Schollenberger L, et al
    A centre-based ambulatory care concept for hidradenitis suppurativa improves disease activity, disease burden and patient satisfaction: results from the randomized controlled EsmAiL trial.
    Br J Dermatol. 2023;189:170-179.
    >> Share

  436. YOTSU RR, Vagamon B, Almamy D, Aka N, et al
    Buruli ulcer: application of thermography for remote diagnosis of a neglected tropical disease.
    Br J Dermatol. 2023;189:236-238.
    >> Share

  437. CHORAGUDI S, Yosipovitch G
    Prurigo nodularis is highly linked with neural sensitization disorders of pain among hospitalized adults in the United States - National Inpatient Sample 2016-2019.
    Br J Dermatol. 2023;189:240-242.
    >> Share

  438. ASFOUR L, Bokhari L, Bhoyrul B, Eisman S, et al
    Treatment of moderate-to-severe alopecia areata with baricitinib in preadolescent children.
    Br J Dermatol. 2023;189:248-250.
    >> Share

  439. SOKOLOFF A, Dykman M, Sokoloff G, Vellody K, et al
    If my hidradenitis had a voice, this is what it would say: the perspective of a young woman with Down syndrome and hidradenitis suppurativa.
    Br J Dermatol. 2023;189:221-222.
    >> Share

  440. MERHI S, Salameh P, Abboud M, Seneschal J, et al
    Facial involvement is reflective of patients' global perception of vitiligo extent.
    Br J Dermatol. 2023;189:188-194.
    >> Share

  441. KIRBY JS, Martorell A, Sayed CJ, Alarcon I, et al
    Understanding the real-world patient journey and unmet needs of people with hidradenitis suppurativa through social media research.
    Br J Dermatol. 2023;189:228-230.
    >> Share

  442. ADAMSON SR, Higgins CL, Veysey E
    Hailey-Hailey disease (benign familial pemphigus) responsive to treatment with ocrelizumab for multiple sclerosis.
    Br J Dermatol. 2023;189:232-234.
    >> Share

  443. LAM M, Spuls PI, Leshem YA, Gerbens LAA, et al
    Reporting of Harmonising Outcome Measures for Eczema (HOME) Core Outcome Set Instruments in randomized clinical trials for systemic treatments in Atopic Dermatitis.
    Br J Dermatol. 2023 Jul 12:ljad237. doi: 10.1093.
    >> Share

  444. KEARNEY N, Kirby B
    The expanding psoriasis therapeutic landscape - reading and understanding clinical trials.
    Br J Dermatol. 2023 Jul 12:ljad238. doi: 10.1093.
    >> Share

  445. CHIU YM, Chiu HY
    Lifetime risk, life expectancy, loss-of-life expectancy, and lifetime healthcare expenditure for Stevens-Johnson syndrome/toxic epidermal necrolysis in Taiwan: follow-up of a nationwide cohort from 2008 to 2019.
    Br J Dermatol. 2023 Jul 10:ljad234. doi: 10.1093.
    >> Share

  446. THOMAS SE, van den Reek JMPA
    Should we prefer biologics over non-biologic agents in psoriasis?
    Br J Dermatol. 2023 Jul 9:ljad231. doi: 10.1093.
    >> Share


  447. Creating the Scale of Alopecia Areata Distress to measure a wide range of negative emotional, social and relationship disease consequences in adults.
    Br J Dermatol. 2023;189:e31.
    >> Share


  448. Safety of treatment with guselkumab in clinical trials for up to 5 years in patients with moderate-to-severe plaque psoriasis.
    Br J Dermatol. 2023;189:e29.
    >> Share


  449. An oncogene-targeted therapy for Merkel cell carcinoma.
    Br J Dermatol. 2023;189:e33.
    >> Share


  450. The use of biosimilars for psoriasis in the UK and Ireland.
    Br J Dermatol. 2023;189:e30.
    >> Share


  451. Better understand about circulating biomarkers and disease severity of chronic hand eczema and atopic dermatitis.
    Br J Dermatol. 2023;189:e34.
    >> Share


  452. Finding treatments to reduce scaling in ichthyosis.
    Br J Dermatol. 2023;189:e32.
    >> Share

  453. WAN J, Shin DB, Syed MN, Abuabara K, et al
    Malignancy risk in patients with atopic dermatitis: a population-based cohort study.
    Br J Dermatol. 2023;189:53-61.
    >> Share


  454. Review of treatments for toenail onychomycosis caused by dermatophytes.
    Br J Dermatol. 2023;189:e28.
    >> Share

  455. GORBATENKO-ROTH K, Wood S, Johnson M, Wallander I, et al
    Beyond health-related quality of life: initial psychometric validation of a new scale for addressing the gap in assessing the full range of alopecia areata psychosocial burden.
    Br J Dermatol. 2023;189:71-79.
    >> Share

  456. GUPTA AK, Venkataraman M, Bamimore MA
    Relative impact of traditional vs. newer oral antifungals for dermatophyte toenail onychomycosis: a network meta-analysis study.
    Br J Dermatol. 2023;189:12-22.
    >> Share

  457. LLOYD-LAVERY A
    Further evidence for the long-term safety of guselkumab.
    Br J Dermatol. 2023;189:10-11.
    >> Share

  458. ITO T, Kageyama R
    Is the Scale of Alopecia Areata Distress a new method of assessing the psychological burden of alopecia areata?
    Br J Dermatol. 2023;189:8.
    >> Share

  459. KERVARREC T
    From genetic characterization to new potential therapeutic options: targeting Bcl-xL in Merkel carcinoma.
    Br J Dermatol. 2023;189:7.
    >> Share

  460. ZIEGLER A, Ebstein F, Shamseldin H, Prouteau C, et al
    Gain-of-function variants in the KDF1 gene cause hidradenitis suppurativa associated with ectodermal dysplasia by stabilizing IkappaB kinase alpha.
    Br J Dermatol. 2023;189:131-132.
    >> Share

  461. HENNIES HC
    Does the understanding of signalling pathways pave the way to therapies for keratinization disorders?
    Br J Dermatol. 2023;189:5-6.
    >> Share

  462. KORTE EWH, Welponer T, Kottner J, van der Werf S, et al
    Heterogeneity of reported outcomes in epidermolysis bullosa clinical research: a scoping review as a first step towards outcome harmonization.
    Br J Dermatol. 2023;189:80-90.
    >> Share

  463. PETROF G, Martinez AE
    Epidermolysis bullosa: time to come together for better outcomes.
    Br J Dermatol. 2023;189:5.
    >> Share

  464. BURGESS IF, Brunton ER
    Head lice: evidence that resistance to physically acting treatments is developing.
    Br J Dermatol. 2023;189:144-145.
    >> Share

  465. CONNOLLY A, Walsh S, Philippidou M, Salisbury J, et al
    Acute hepatic failure in trimethoprim-induced drug rash with eosinophilia and systemic symptoms (DRESS).
    Br J Dermatol. 2023;189:140-141.
    >> Share

  466. CROWDER D, Herbert S, Haughton R
    Psychosocial impact of pyoderma gangrenosum: a patient perspective.
    Br J Dermatol. 2023;189:125-128.
    >> Share

  467. WARREN RB, Basey V, Lynam A, Curtis C, et al
    The risk of venous thromboembolism in atopic dermatitis: A matched cohort analysis in UK primary care.
    Br J Dermatol. 2023 Jul 7:ljad212. doi: 10.1093.
    >> Share

  468. YEN H, Chiu YE
    More than skin deep: Getting on the same page for mental health in children and young people with skin conditions.
    Br J Dermatol. 2023 Jul 7:ljad232. doi: 10.1093.
    >> Share

  469. KWIATKOWSKA D, Reich A
    Seeking new topical therapies in psoriasis.
    Br J Dermatol. 2023 Jul 7:ljad233. doi: 10.1093.
    >> Share

  470. ERTUS C, Scailteux LM, Lescoat A, Berthe P, et al
    Major adverse cardiovascular events in patients treated with oral Janus kinase inhibitors for atopic dermatitis: a systematic review and meta-analysis.
    Br J Dermatol. 2023 Jul 6:ljad229. doi: 10.1093.
    >> Share

  471. GOLLINS CE, Coates LC
    Validation of a new measure of patient global assessment in psoriasis.
    Br J Dermatol. 2023 Jul 6:ljad228. doi: 10.1093.
    >> Share

  472. TSAI YC, Schlaepfer T, Ignatova D, Chang YT, et al
    Boost of innate immunity cytokines as biomarkers of response to extracorporeal photopheresis in leukaemic cutaneous T-cell lymphoma patients.
    Br J Dermatol. 2023 Jul 6:ljad220. doi: 10.1093.
    >> Share

  473. GIUFFRIDA R, Zanin Poletto G, Guarneri F, Conforti C, et al
    Nevus count on the face for the identification of patients with higher risk of melanoma.
    Br J Dermatol. 2023 Jul 6:ljad216. doi: 10.1093.
    >> Share

  474. OLLECH A, Lefferdink R, Sheth A, Blumstein A, et al
    Systemic Immunosuppressive Therapies for Children with Refractory Atopic Dermatitis: A Large Real-Life Cohort Study.
    Br J Dermatol. 2023 Jul 5:ljad222. doi: 10.1093.
    >> Share

  475. HONG CH, Lee CH
    A nationwide UK cohort study reveals an association between atopic dermatitis and venous thromboembolism.
    Br J Dermatol. 2023 Jul 5:ljad221. doi: 10.1093.
    >> Share

  476. JUNEJO MH, Wolfe I, Patel J, Duus E, et al
    Use of the Dermatology Life Quality Index suite of patient reported outcome measures in skin neglected tropical diseases.
    Br J Dermatol. 2023 Jul 3:ljad217. doi: 10.1093.
    >> Share

  477. RIBERO S, Quaglino P, Roccuzzo G
    Predicting progression in very thin melanoma: the challenge of the next decade?
    Br J Dermatol. 2023 Jul 3:ljad218. doi: 10.1093.
    >> Share

    June 2023
  478. TSAI TF
    Heterogeneity of generalized pustular psoriasis in multi-ethnic Johor Bahru, Malaysia.
    Br J Dermatol. 2023 Jun 28:ljad197. doi: 10.1093.
    >> Share

  479. BARRABES-TORRELLA C, Arandes-Marcocci J, Armillas-Lliteras L, Posada-Caez RA, et al
    Sarcomatoid transformation of a basal cell carcinoma following treatment with hedgehog inhibitors.
    Br J Dermatol. 2023 Jun 28:ljad206. doi: 10.1093.
    >> Share

  480. LUO M, Zhu C, Lin J, Lin L, et al
    Bidirectional Mendelian randomization analysis did not indicate a causal relationship between atopic dermatitis and COVID-19.
    Br J Dermatol. 2023 Jun 27:ljad208. doi: 10.1093.
    >> Share

  481. OGAWA-MOMOHARA M, Muro Y, Murase C, Taki T, et al
    Allergen-specific IgG4 increase in atopic dermatitis with long-term dupilumab use.
    Br J Dermatol. 2023 Jun 27:ljad207. doi: 10.1093.
    >> Share

  482. HAN JH, Ju HJ, Kang H, Lee JH, et al
    Autoimmune, Inflammatory, Allergic, and Neuropsychiatric Outcomes of Offspring Born to Mothers with Vitiligo: A Nationwide Population-based Birth Cohort Study of Korea.
    Br J Dermatol. 2023 Jun 19:ljad196. doi: 10.1093.
    >> Share

  483. YU N, Peng C, Zhou J, Gu J, et al
    Measurement properties of the Patient Global Assessment numerical rating scale in moderate-to-severe psoriasis.
    Br J Dermatol. 2023 Jun 13:ljad188. doi: 10.1093.
    >> Share

  484. MCPHERSON T, Ravenscroft J, Ali R, Barlow R, et al
    British Society for Paediatric and Adolescent Dermatology (BSPAD) assessment and support of mental health in children and young people (CYP) with skin conditions: A multi-disciplinary expert consensus statement and recommendations.
    Br J Dermatol. 2023 Jun 9:ljad193. doi: 10.1093.
    >> Share

  485. KAKISH H, Sun J, Zheng DX, Ali Ahmed F, et al
    Predictors of Sentinel Lymph Node Metastasis in Very Thin Invasive Melanomas.
    Br J Dermatol. 2023 Jun 8:ljad195. doi: 10.1093.
    >> Share

  486. AKIYAMA M
    Cathepsin and cutaneous disorders of cornification and inflammation: Their close links.
    Br J Dermatol. 2023 Jun 8:ljad190. doi: 10.1093.
    >> Share

  487. LAX SJ, Roberts A, Cliffe E, Ramesh G, et al
    Public views are needed for skin colour scales.
    Br J Dermatol. 2023 Jun 8:ljad189. doi: 10.1093.
    >> Share

  488. AGUILAR-CALDERON PE, Reyes-Soto MA, Sanchez-Meza E, Brown-Herrera A, et al
    Melanonychia as a manifestation of chronic lead poisoning.
    Br J Dermatol. 2023 Jun 7:ljad194. doi: 10.1093.
    >> Share

  489. KIRCIK LH, Alonso-Llamazares J, Bhatia N, Bukhalo M, et al
    Once-daily roflumilast foam 0.3% for scalp and body psoriasis: A randomized, double-blind, vehicle-controlled phase 2b study.
    Br J Dermatol. 2023 Jun 5:ljad182. doi: 10.1093.
    >> Share

  490. VERGARA IA, Stark MS
    One Step Closer to Improving Melanoma Diagnosis and Prognosis with Liquid Biopsies.
    Br J Dermatol. 2023 Jun 3:ljad185. doi: 10.1093.
    >> Share

    May 2023
  491. MORAN B, Smith CM, Zabarowski A, Ryan M, et al
    Targeting the NLRP3 inflammasome reduces inflammation in hidradenitis suppurativa skin.
    Br J Dermatol. 2023 May 27:ljad184. doi: 10.1093.
    >> Share

  492. MUTO Y, Kambayashi Y, Kato H, Fukushima S, et al
    Postoperative adjuvant therapy for120 melanoma patients, including acral and mucosal subtypes: A multicenter, observational study of two-year follow-up results.
    Br J Dermatol. 2023 May 27:ljad183. doi: 10.1093.
    >> Share

  493. LAWSON A, Wininger M, Wang M, Steger M, et al
    Premenarchal Lichen Sclerosus: A Multicenter Examination of the Novel Diagnostic Tool, the SWIFT Model.
    Br J Dermatol. 2023 May 26:ljad180. doi: 10.1093.
    >> Share

  494. ALABAS OA, Mason KJ, Yiu ZZN, Warren RB, et al
    Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: A cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Br J Dermatol. 2023 May 25:ljad179. doi: 10.1093.
    >> Share


  495. Results from 1 year of treatment with lebrikizumab for atopic dermatitis.
    Br J Dermatol. 2023;188:e43.
    >> Share


  496. Skin cancer incidence and survival rates in England, 2013-2019.
    Br J Dermatol. 2023;188:e45.
    >> Share


  497. Atopic eczema: palmar patterns associated with filaggrin variants, disease severity and barrier function in a South Asian population.
    Br J Dermatol. 2023;188:e46.
    >> Share


  498. Atopic dermatitis across the globe: differences in prevalence and access to treatments.
    Br J Dermatol. 2023;188:e42.
    >> Share

  499. PANDYA R, Kleitsch J, Werth VP
    Trial of intravenous immunoglobulin in dermatomyositis: a critically appraised research paper.
    Br J Dermatol. 2023;188:738-739.
    >> Share

  500. GARG A, Rawal S, Akilov O, Alavi A, et al
    Factors associated with disease-specific life impact in patients with hidradenitis suppurativa: results from the Global VOICE project.
    Br J Dermatol. 2023;188:808-810.
    >> Share

  501. ALONSO-ALONSO R, Rodriguez M, Garcia-Diaz N, Tomas-Roca L, et al
    NanoString analysis of mycosis fungoides reveals individual molecular identity.
    Br J Dermatol. 2023;188:812-814.
    >> Share

  502. O'CONNELL KA, Schaefer M, Atzmony L, Vleugels RA, et al
    Clinical features in adults with acquired cutis laxa: a retrospective review.
    Br J Dermatol. 2023;188:800-816.
    >> Share

  503. THOMAS BR, Tan XL, Van Duijvenboden S, Hogan SC, et al
    Deep palmar phenotyping in atopic eczema: patterns associated with filaggrin variants, disease severity and barrier function in a South Asian population.
    Br J Dermatol. 2023;188:785-792.
    >> Share

  504. CHOSIDOW O, Chang AY
    The skin of people experiencing homelessness: more (known) is less (neglected).
    Br J Dermatol. 2023;188:694-695.
    >> Share


  505. Two melanoma genes (MITF and MC1R) interact to cause different risks.
    Br J Dermatol. 2023;188:e44.
    >> Share

  506. BECHMAN K, Hayes JF, Mathewman J, Henderson A, et al
    Electronic screening for mental illness in patients with psoriasis.
    Br J Dermatol. 2023 May 24:ljad141. doi: 10.1093.
    >> Share

  507. HIJNEN D, Olydam J
    Prediction of response to dupilumab treatment.
    Br J Dermatol. 2023;188:e41.
    >> Share

  508. POGORZELSKA-DYRBUS J, Szepietowski JC
    Melanoma cells in optical super-high magnification dermoscopy.
    Br J Dermatol. 2023 May 22:ljad168. doi: 10.1093.
    >> Share


  509. Correction to: 319 Effects of omega-3 fatty acid supplementation on atopic dermatitis.
    Br J Dermatol. 2023 May 22:ljad154. doi: 10.1093.
    >> Share

  510. TAKEICHI T, Ito Y, Lee JYW, Murase C, et al
    KLK11 ichthyosis: large truncal hyperkeratotic pigmented plaques underscore a distinct autosomal dominant disorder of cornification.
    Br J Dermatol. 2023 May 22:ljad082. doi: 10.1093.
    >> Share

  511. VROOM IR, Hulshof MA, Schelhaas W, Koning SN, et al
    Differences and similarities in teledermatological primary care case histories between people with skin of color and White skin.
    Br J Dermatol. 2023 May 20:ljad164. doi: 10.1093.
    >> Share

  512. ROMITI R, Martins LPF, Santana YRT, Timbo RV, et al
    Prevalence of psoriasis and other autoimmune skin diseases in a recently contacted Amerindian community in the Auaris region, Yanomami territory, Brazil.
    Br J Dermatol. 2023 May 20:ljad165. doi: 10.1093.
    >> Share

  513. SPEKHORST LS, Boesjes CM, Loman L, Zuithoff NPA, et al
    Successful tapering of dupilumab in atopic dermatitis patients with low disease activity: a large pragmatic daily practice study from the BioDay registry.
    Br J Dermatol. 2023 May 13:ljad159. doi: 10.1093.
    >> Share

  514. PETERKNECHT E, Scarisbrick J
    Skin Swabs in the Skin Lymphoma Clinic - From Swab to Treatment.
    Br J Dermatol. 2023 May 13:ljad160. doi: 10.1093.
    >> Share

  515. CHOON SE, Wright AK, Griffiths CEM, Wong KW, et al
    Incidence and prevalence of generalised pustular psoriasis in multi-ethnic Johor Bahru, Malaysia: a population-based cohort study using routinely captured electronic health records in Teleprimary Care (TPC(R)) clinical information system from 2010 to
    Br J Dermatol. 2023 May 10:ljad158. doi: 10.1093.
    >> Share

  516. CRANWELL WC, Sinclair RD
    Can brepocitinib be formulated into an effective topical therapy to treat mild-to-moderate chronic plaque psoriasis?
    Br J Dermatol. 2023 May 8:ljad157. doi: 10.1093.
    >> Share

  517. DAN J, Sprow G, Concha J, Patel J, et al
    A comparison of the efficacy of Skindex-16 and Skindex-29 in dermatomyositis.
    Br J Dermatol. 2023 May 5:ljad133. doi: 10.1093.
    >> Share

  518. VAN LAAR R, Latif B, King S, Love C, et al
    Validation of microRNA Liquid Biopsy for Diagnosis and Risk Stratification of Invasive Cutaneous Melanoma.
    Br J Dermatol. 2023 May 5:ljad137. doi: 10.1093.
    >> Share

  519. BZIOUECHE H, Boniface K, Drullion C, Marchetti S, et al
    Impact of House-Dust-Mite in Vitiligo Skin: Environmental Contribution to Increased Cutaneous Immunity and Melanocyte Detachment.
    Br J Dermatol. 2023 May 4:ljad148. doi: 10.1093.
    >> Share

  520. FREEMAN EE, Garcia-Doval I, Naldi L, Hay RJ, et al
    COVID-19 and the skin, three years on: long term impacts, emerging trends and clinical practice.
    Br J Dermatol. 2023 May 3:ljad131. doi: 10.1093.
    >> Share

  521. PATRA S, Karat TP, Kaur M
    Buried dermal interrupted or vertical mattress: what to prefer for dermal layer suturing of surgical skin wounds?
    Br J Dermatol. 2023 May 3:ljad132. doi: 10.1093.
    >> Share


  522. Correction to: Local cutaneous refractoriness to sun exposure following omalizumab injections in solar urticaria.
    Br J Dermatol. 2023 May 2:ljad130. doi: 10.1093.
    >> Share

    April 2023
  523. FLOHR C, Irvine AD, Cork MJ, Simpson EL, et al
    Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitis.
    Br J Dermatol. 2023 Apr 30:ljad124. doi: 10.1093.
    >> Share

  524. WARREN RB, Reich A, Kaszuba A, Placek W, et al
    Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody for the Treatment of Generalised Pustular Psoriasis: Results from the Phase 2 GALLOP Trial.
    Br J Dermatol. 2023 Apr 30:ljad083. doi: 10.1093.
    >> Share

  525. ARENTS BWM
    Intriguing findings on lebrikizumab for treating moderate-to-severe atopic dermatitis.
    Br J Dermatol. 2023 Apr 24:ljad068. doi: 10.1093.
    >> Share

  526. BAO C, Xu Q, Xiao Z, Wang H, et al
    Abrocitinib as a novel treatment for lichen sclerosus.
    Br J Dermatol. 2023 Apr 24:ljad129. doi: 10.1093.
    >> Share

  527. GLEESON D, Mahil SK
    Imsidolimab: an emerging biologic therapy for generalised pustular psoriasis.
    Br J Dermatol. 2023 Apr 20:ljad128. doi: 10.1093.
    >> Share


  528. Immunity 6 months after COVID-19 vaccination in patients with psoriasis treated with immunomodulatory drugs.
    Br J Dermatol. 2023;188:e38.
    >> Share


  529. Serum biomarker analysis to identify subtypes of atopic dermatitis in China and to help with predicting the effectiveness of treatment with dupilumab.
    Br J Dermatol. 2023;188:e37.
    >> Share


  530. The real-world effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for treating moderate-to-severe psoriasis.
    Br J Dermatol. 2023;188:e35.
    >> Share


  531. Neutrophil migration in hidradenitis suppurativa.
    Br J Dermatol. 2023;188:e36.
    >> Share

  532. WOLK K
    Hope for a new therapy for hidradenitis suppurativa: blocking of granulocyte colony-stimulating factor receptor.
    Br J Dermatol. 2023;188:590.
    >> Share

  533. DUDINK K, Bouwman K, Chen Y, DePrimo SE, et al
    Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study.
    Br J Dermatol. 2023;188:601-609.
    >> Share

  534. STARRETT GJ, Lee JW, Chatterjee S, Jedrych JJ, et al
    Detection of extensive host-virus DNA hybrids in human polyomavirus 7-associated pruritic rash.
    Br J Dermatol. 2023;188:675-677.
    >> Share

  535. MENDES-BASTOS P, Martorell A, Bettoli V, Matos AP, et al
    The use of ultrasound and magnetic resonance imaging in the management of hidradenitis suppurativa: a narrative review.
    Br J Dermatol. 2023;188:591-600.
    >> Share

  536. WARK KJL, Der Sarkissian SA, Tatian A, Woods J, et al
    The association between pilonidal sinus disease and hidradenitis suppurativa: a systematic review and meta-analysis.
    Br J Dermatol. 2023;188:673-675.
    >> Share

  537. SCHUSTER B, Gallinger J, Philipp-Dormston WG, Vasel M, et al
    Less confident, successful and happy: patients with post-acne hyperpigmentation are stigmatized.
    Br J Dermatol. 2023;188:682-684.
    >> Share

  538. FREW JW
    In search of therapeutic biomarkers to interleukin-23 antagonism in hidradenitis suppurativa.
    Br J Dermatol. 2023;188:588-589.
    >> Share

  539. SANTOS LL, Zhu Z, Brown K, Kirby JS, et al
    Initial validation of the Hidradenitis Suppurativa Quality of Life tool in a clinical trial setting.
    Br J Dermatol. 2023;188:672-673.
    >> Share

  540. GAMELL C, Bankovacki A, Scalzo-Inguanti K, Sedgmen B, et al
    CSL324, a granulocyte colony-stimulating factor receptor antagonist, blocks neutrophil migration markers that are upregulated in hidradenitis suppurativa.
    Br J Dermatol. 2023;188:636-648.
    >> Share

  541. VALENTI M, Costanzo A
    Nonadherence to immune-modifying therapies during the COVID-19 pandemic: the crucial role of doctor-patient communication in avoiding drug discontinuation.
    Br J Dermatol. 2023;188:586-590.
    >> Share

  542. BURDEN AD, Bachelez H, Choon SE, Marrakchi S, et al
    The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activity.
    Br J Dermatol. 2023 Apr 19:ljad071. doi: 10.1093.
    >> Share

  543. BEN ABDALLAH H, Johansen C
    Transmembrane protein 232 (TMEM232) regulates inflammation in experimental models of atopic dermatitis.
    Br J Dermatol. 2023 Apr 17:ljad127. doi: 10.1093.
    >> Share

  544. TAKEICHI T, Muro Y, Akiyama M
    Ichthyotic skin phenotype induced by the chronic activation of Toll-like receptor 2, and autoinflammation.
    Br J Dermatol. 2023 Apr 17:ljad122. doi: 10.1093.
    >> Share

  545. LALLAS A
    Which melanoma patients are at priority for monitoring to detect new primary melanoma?
    Br J Dermatol. 2023 Apr 17:ljad125. doi: 10.1093.
    >> Share

  546. SBIDIAN E
    A multistep approach from scoping review to strong evidence: biomarkers in psoriasis.
    Br J Dermatol. 2023 Apr 13:ljac101. doi: 10.1093.
    >> Share

  547. QUAADE AS, Wang X, Solberg JBK, Ulrich NH, et al
    Circulating biomarkers are associated with disease severity of chronic hand eczema and atopic dermatitis.
    Br J Dermatol. 2023 Apr 13:ljad110. doi: 10.1093.
    >> Share

  548. DESCATHA A, Ezzedine K, Le Roux G
    A case of Paederus Dermatitis in Western Europe: a signal for One Health -One World concept for the dermatologist.
    Br J Dermatol. 2023 Apr 13:ljad103. doi: 10.1093.
    >> Share

  549. KELLY L, Coote L, Dinnes J, Fleming C, et al
    Key issues when considering adopting a skin cancer diagnostic tool which uses artificial intelligence.
    Br J Dermatol. 2023 Apr 12:ljad080. doi: 10.1093.
    >> Share

  550. VITTRUP I
    Malignancy risk in atopic dermatitis: heterogenous effects and perspectives.
    Br J Dermatol. 2023 Apr 11:ljad119. doi: 10.1093.
    >> Share

  551. IBRAHIM LS, Venables ZC, McPhail S, Levell NJ, et al
    Missing melanomas in England during the COVID-19 pandemic: 2,485 fewer melanoma diagnoses in 2020 than in 2019.
    Br J Dermatol. 2023 Apr 10:ljad117. doi: 10.1093.
    >> Share

  552. GRIFFIN L, O'Reilly P, Murphy M, Prendergast G, et al
    Photoprotection and Skin Cancer Education - the Experiences of Renal Transplant Recipients, a qualitative study. Why the 'personal touch' is important.
    Br J Dermatol. 2023 Apr 6:ljad116. doi: 10.1093.
    >> Share

  553. LEBWOHL MG, Merola JF, Rowland K, Miller M, et al
    Safety of Guselkumab Treatment for up to 5 Years in Patients With Moderate-to-Severe Psoriasis: Pooled Analyses Across Seven Clinical Trials With Greater Than 8600 Patient-Years of Exposure.
    Br J Dermatol. 2023 Apr 6:ljad115. doi: 10.1093.
    >> Share

  554. FUJISAWA Y, Namikawa K, Yoshino K, Kiniwa Y, et al
    Combined use of nivolumab and ipilimumab among Japanese melanoma patients: Multi-center, retrospective study of 111 cases.
    Br J Dermatol. 2023 Apr 5:ljad114. doi: 10.1093.
    >> Share

  555. PHAN DB, Bewley AP, Smith CH, Mackenzie T, et al
    Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: A drug utilisation study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Br J Dermatol. 2023 Apr 5:ljad107. doi: 10.1093.
    >> Share

  556. SPELMAN L
    Safety and longevity of biologic treatment in the setting of moderate to severe psoriasis - enhancing the body of evidence.
    Br J Dermatol. 2023 Apr 3:ljad112. doi: 10.1093.
    >> Share

  557. GUNTHER C
    Rapid response of cutaneous lupus erythematosus to treatment with the type I interferon receptor antagonist anifrolumab.
    Br J Dermatol. 2023 Apr 1:ljad111. doi: 10.1093.
    >> Share

    March 2023
  558. TORRELO A, Rewerska B, Galimberti M, Paller A, et al
    Efficacy and safety of baricitinib in combination with topical corticosteroids in pediatric patients with moderate-to-severe atopic dermatitis with inadequate response to topical corticosteroids: results from a phase 3, randomized, double-blind, place
    Br J Dermatol. 2023 Mar 31:ljad096. doi: 10.1093.
    >> Share


  559. Factors associated with mental illness in adults with atopic eczema or psoriasis.
    Br J Dermatol. 2023;188:e27.
    >> Share


  560. Quality of life of Bangladeshi children and young adults with atopic eczema and their families in East London.
    Br J Dermatol. 2023;188:e33.
    >> Share


  561. Parent and child experiences of skin conditions and views on mindfulness-based support.
    Br J Dermatol. 2023;188:e32.
    >> Share


  562. Effects of air pollution on psoriasis in Wuhan, China.
    Br J Dermatol. 2023;188:e30.
    >> Share


  563. Use of proton pump inhibitors in people taking BRAF/MEK inhibitors for metastatic melanoma.
    Br J Dermatol. 2023;188:e29.
    >> Share


  564. What do parents/carers of children with eczema and young people with eczema think of two websites to help them to manage eczema?
    Br J Dermatol. 2023;188:e31.
    >> Share

  565. KRIDIN K, Mruwat N, Amber KT, Ludwig RJ, et al
    Risk of infections in patients with pemphigus treated with rituximab vs. azathioprine or mycophenolate mofetil: a large-scale global cohort study.
    Br J Dermatol. 2023;188:499-505.
    >> Share

  566. BOZONNAT A, Polivka L, Leclerc-Mercier S, Luscan R, et al
    Severe tracheal involvement in type XVII collagen junctional epidermolysis bullosa.
    Br J Dermatol. 2023;188:564-566.
    >> Share

  567. DRUMM C, Chawla S, Kravvas G, Spencer A, et al
    Representation of genital dermatoses in dermatological literature.
    Br J Dermatol. 2023;188:563-564.
    >> Share

  568. PIMENTEL MA, Li MM, Noe MH, Latour E, et al
    Features that define clinical severity of ulcerative pyoderma gangrenosum: a Delphi consensus study of experts and patients on behalf of the US Medical Dermatology Society.
    Br J Dermatol. 2023;188:566-568.
    >> Share

  569. GREENWELL K, Sivyer K, Howells L, Steele M, et al
    'Eczema shouldn't control you; you should control eczema': qualitative process evaluation of online behavioural interventions to support young people and parents/carers of children with eczema.
    Br J Dermatol. 2023;188:506-513.
    >> Share

  570. TAWFIK SS, Thomas BR, Kelsell DP, Grigg J, et al
    Dermatology Quality of Life Index scores in Bangladeshi patients with atopic eczema and their families in East London.
    Br J Dermatol. 2023;188:524-532.
    >> Share

  571. STEYN M, Ayis S, O'Connor J, Lakhan MK, et al
    Dapsone therapy for hidradenitis suppurativa: a retrospective review of characteristics and treatment outcomes in a cohort of 122 patients in a tertiary dermatology setting.
    Br J Dermatol. 2023;188:573-574.
    >> Share

  572. CAZZANIGA S, Naldi L, Borradori L
    Rituximab and risk of infections in patients with pemphigus: answers from a global population-based cohort study.
    Br J Dermatol. 2023;188:454-455.
    >> Share

  573. MAGIN P, Fisher K
    Online behavioural interventions for children and young people with atopic eczema: refining the way forward.
    Br J Dermatol. 2023;188:453.
    >> Share

  574. GLEESON D, Barker JNWN, Capon F, Pink AE, et al
    Are Janus kinase inhibitors an effective treatment for palmoplantar pustulosis? A critically appraised topic.
    Br J Dermatol. 2023;188:471-473.
    >> Share

  575. JIANG SW, Petty AJ, Jacobs JL, Robinson C, et al
    Association between age at symptom onset and disease severity in older patients with hidradenitis suppurativa.
    Br J Dermatol. 2023;188:555-576.
    >> Share

  576. BELZER A, Leasure AC, Damsky W, Cohen JM, et al
    The association of anxiety with granuloma annulare: a case-control study of the National Institutes of Health 'All of Us' research programme.
    Br J Dermatol. 2023;188:558-560.
    >> Share

  577. VANCE TM, Li T, Cho E, Drucker AM, et al
    Prenatal antibiotic use and subsequent risk of atopic eczema.
    Br J Dermatol. 2023;188:561-563.
    >> Share

  578. CAPOZZA K
    Lost in translation: understanding the experience of atopic eczema among non-English-speaking families.
    Br J Dermatol. 2023;188:456-457.
    >> Share

  579. DIFFEY BL
    Sun protection: false beliefs and misguided advocacy.
    Br J Dermatol. 2023;188:552-554.
    >> Share

  580. BLAUVELT A, Thyssen JP, Guttman-Yassky E, Bieber T, et al
    Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
    Br J Dermatol. 2023 Mar 30:ljad022. doi: 10.1093.
    >> Share


  581. Potential new solution to reduce skin complications and improve quality of life in people living with a stoma.
    Br J Dermatol. 2023;188:e28.
    >> Share

  582. ASCOTT A, van Bodegraven B, Vernon S, Orteu CH, et al
    The geographical variation of melanoma, basal and squamous cell carcinoma in England.
    Br J Dermatol. 2023 Mar 30:ljad100. doi: 10.1093.
    >> Share

  583. FAN K, Srinivas N, Kubat L, Gravemeyer J, et al
    B-cell lymphoma extra-large (Bcl-xL) is a promising drug target in Merkel cell carcinoma.
    Br J Dermatol. 2023 Mar 30:ljad099. doi: 10.1093.
    >> Share

  584. DOOLAN BJ, Rayinda T, Chiu FP, McGrath JA, et al
    A review of genotrichoses and hair pathology associated with inherited skin diseases.
    Br J Dermatol. 2023 Mar 29:ljad102. doi: 10.1093.
    >> Share

  585. BRUNO W
    Joint contribution of MC1R and MITF alleles to melanoma risk in the age of polygenic risk scores.
    Br J Dermatol. 2023 Mar 28:ljad097. doi: 10.1093.
    >> Share

  586. TAGOE H, Hassan S, Youssef G, Heywood W, et al
    Chronic activation of Toll-like receptor 2 induces an ichthyotic skin phenotype.
    Br J Dermatol. 2023 Mar 27:ljad095. doi: 10.1093.
    >> Share

  587. LANDIS MN, Smith SR, Berstein G, Fetterly G, et al
    Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb, randomised, double-blind, vehicle-controlled, parallel-group study.
    Br J Dermatol. 2023 Mar 27:ljad098. doi: 10.1093.
    >> Share

  588. STROBER B, Tada Y, Mrowietz U, Lebwohl M, et al
    Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial.
    Br J Dermatol. 2023 Mar 27:ljad035. doi: 10.1093.
    >> Share

  589. NI Y, Watts CG, Scolyer RA, Madronio C, et al
    Risk of developing a second primary melanoma after a first primary melanoma in a population-based Australian cohort.
    Br J Dermatol. 2023 Mar 22:ljad076. doi: 10.1093.
    >> Share

  590. SINIKUMPU SP, Jokelainen J, Huilaja L
    The association between atopic dermatitis and acne: a retrospective Finnish nationwide registry study.
    Br J Dermatol. 2023 Mar 22:ljad086. doi: 10.1093.
    >> Share

  591. RAGAMIN A, Tupker RA, de Graaf M, Rustemeyer T, et al
    Investigator Global Assessment for impetiginization in Atopic Dermatitis (IGA impetiginization): Development and initial reliability testing.
    Br J Dermatol. 2023 Mar 22:ljad085. doi: 10.1093.
    >> Share

  592. CARTER LM, Wigston Z, Laws P, Vital EM, et al
    Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers.
    Br J Dermatol. 2023 Mar 22:ljad089. doi: 10.1093.
    >> Share

  593. BLAUVELT A, Thaci D, Papp KA, Ho V, et al
    Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials.
    Br J Dermatol. 2023 Mar 22:ljad081. doi: 10.1093.
    >> Share

  594. PATHMARAJAH P, Corso R, Salam A, Shah G, et al
    Neutropenia in patients on dupilumab for atopic dermatitis: a case series and review of trial data.
    Br J Dermatol. 2023 Mar 17:ljad038. doi: 10.1093.
    >> Share

  595. HAN J, Cai X, Qin S, Zhang Z, et al
    TMEM232 Promotes the Inflammatory Response in Atopic Dermatitis via NF-kappaB and STAT3 Signaling Pathways.
    Br J Dermatol. 2023 Mar 17:ljad078. doi: 10.1093.
    >> Share

  596. SINGH N, Schikowski T
    Skin diseases and emerging determinants: the need for interactive research.
    Br J Dermatol. 2023 Mar 14:ljad008. doi: 10.1093.
    >> Share

  597. DE VRIES E
    The important but difficult exercise of getting valid descriptive skin cancer data.
    Br J Dermatol. 2023 Mar 10:ljad065. doi: 10.1093.
    >> Share

  598. DRAELOS ZD, Adam DN, Hong CH, Lebwohl MG, et al
    Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial.
    Br J Dermatol. 2023 Mar 9:ljad060. doi: 10.1093.
    >> Share

  599. MOSAM A, Todd G
    Global epidemiology and disparities in atopic dermatitis.
    Br J Dermatol. 2023 Mar 7:ljad042. doi: 10.1093.
    >> Share

  600. WALLINGFORD CK, Demeshko A, Krishnankutty Krishnakripa A, Smit DJ, et al
    MC1R 'r' allele does not increase melanoma risk in MITF E318K carriers.
    Br J Dermatol. 2023 Mar 5:ljad041. doi: 10.1093.
    >> Share

  601. DE DIOS MA, Arroyo-Andres J, Rubio-Muniz C, Concepcion Garrido M, et al
    Cutaneous features at injection sites of intravenous mephedrone.
    Br J Dermatol. 2023 Mar 5:ljad064. doi: 10.1093.
    >> Share

  602. OLSEN CM, Gordon LG, Carter SM, Whiteman DC, et al
    The ethical implications of opportunistic detection of melanoma in clinical care.
    Br J Dermatol. 2023 Mar 3:ljad055. doi: 10.1093.
    >> Share

  603. GHIASVAND R, Berge LAM, Andreassen BK, Green AC, et al
    Statin use and risk of cutaneous melanoma: A nationwide nested case-control study.
    Br J Dermatol. 2023 Mar 3:ljad057. doi: 10.1093.
    >> Share

  604. DRUCKER AM
    Atopic dermatitis in 2023 and beyond.
    Br J Dermatol. 2023 Mar 2:ljad053. doi: 10.1093.
    >> Share

    February 2023
  605. VAN BODEGRAVEN B, Vernon S, Eversfield C, Board R, et al
    "Get Data Out" Skin: national cancer registry incidence and survival rates for all registered skin tumour groups for 2013-2019 in England.
    Br J Dermatol. 2023 Feb 23:ljad033. doi: 10.1093.
    >> Share


  606. Greater understanding about other diseases that are closely linked to having a diagnosis of psoriasis.
    Br J Dermatol. 2023;188:e23.
    >> Share


  607. Atopic dermatitis and school performance in children and young adults.
    Br J Dermatol. 2023;188:e21.
    >> Share


  608. New findings about what drives inflammation in hidradenitis suppurativa may lead to new treatments.
    Br J Dermatol. 2023;188:e24.
    >> Share


  609. Skin cancer and ultraviolet-radiation exposure in different jobs.
    Br J Dermatol. 2023;188:e22.
    >> Share

  610. JAYASINGHE D, Koh U, Plasmeijer EI, Menzies SW, et al
    The dynamic nature of naevi in adulthood: prospective population-based study using three-dimensional total-body photography.
    Br J Dermatol. 2023;188:437-439.
    >> Share

  611. FAN B, Wang M
    Tofacitinib in recalcitrant bullous pemphigoid: a report of seven cases.
    Br J Dermatol. 2023;188:432-434.
    >> Share

  612. NILSSON SF, Ali Z, Laursen TM, Thyssen JP, et al
    Association of homelessness and skin conditions: A Danish population-based cohort study.
    Br J Dermatol. 2023 Feb 22:ljad040. doi: 10.1093.
    >> Share

  613. VALENTI M, Costanzo A
    Efficacy and safety of switching psoriatic patients to bimekizumab: new evidence from clinical trials.
    Br J Dermatol. 2023;188:316-317.
    >> Share

  614. EADIE E, Josso M, Touti R, Renoux P, et al
    Commercial visible-light protecting sunscreens for photosensitive individuals.
    Br J Dermatol. 2023;188:445-447.
    >> Share

  615. SUN X, Sheng A, Xu AE
    Successful treatment of vitiligo with crisaborole ointment: a report of two cases.
    Br J Dermatol. 2023;188:436-437.
    >> Share

  616. LI HO, Bailey AMJ, Pastukhova E, Tan MG, et al
    Comorbid diagnosis of systemic lupus erythematosus in vitiligo: a systematic review and meta-analysis.
    Br J Dermatol. 2023;188:440-441.
    >> Share

  617. FAGAN N, Doherty GA, Meah N, Sinclair R, et al
    Cross-specialty identification of the JAK1 inhibitor trial agent filgotinib as a potential therapy for alopecia areata.
    Br J Dermatol. 2023;188:442-443.
    >> Share

  618. BHATE K, Mansfield KE, Sinnott SJ, Margolis DJ, et al
    Long-term oral antibiotic use in people with acne vulgaris in UK primary care: a drug utilization study.
    Br J Dermatol. 2023;188:361-371.
    >> Share

  619. GIAMARELLOS-BOURBOULIS EJ
    Keratinocytes as drivers of hidradenitis suppurativa inflammation: need for priming.
    Br J Dermatol. 2023;188:318-319.
    >> Share

  620. KRAJEWSKI PK, Matusiak L, Szepietowski JC
    Adipokines as an important link between hidradenitis suppurativa and obesity: a narrative review.
    Br J Dermatol. 2023;188:320-327.
    >> Share

  621. AGARWALA S, Mata DA, Safeer LZ, Hafeez F, et al
    Proliferative actinic keratoses are associated with adverse clinical outcomes relative to actinic keratoses without a proliferative growth pattern.
    Br J Dermatol. 2023;188:439-440.
    >> Share

  622. COLLINS MS, Ali S, Wiss IP, Senna MM, et al
    Retrospective analysis of the risk of hyperkalaemia in women older than 65 years of age prescribed spironolactone for female-pattern hair loss.
    Br J Dermatol. 2023;188:429-447.
    >> Share

  623. SMITH H, Hussain W
    Is it time we changed the way we manage melanoma in situ of the trunk and limbs?
    Br J Dermatol. 2023 Feb 18:ljad031. doi: 10.1093.
    >> Share

  624. VON KOBYLETZKI L
    Which patients with atopic eczema and psoriasis develop depression, anxiety, and severe mental illness: is the evidence clear?
    Br J Dermatol. 2023 Feb 15:ljad009. doi: 10.1093.
    >> Share

  625. OLSEN CM, Pandeya N, Whiteman DC
    The rise in thick melanomas: can early detection reduce the burden?
    Br J Dermatol. 2023 Feb 15:ljad034. doi: 10.1093.
    >> Share

  626. PUIG L
    Psoriasis treatment does not impair the immunogenicity of ChAOx1-S[recombinant] COVID-19 vaccination.
    Br J Dermatol. 2023;188:163-165.
    >> Share


  627. Responses to AstraZeneca COVID-19 vaccines in patients with immune-mediated skin diseases.
    Br J Dermatol. 2023;188:e19.
    >> Share


  628. Photodamage and photoprotection in populations with skin of colour.
    Br J Dermatol. 2023;188:e11.
    >> Share


  629. Greater understanding about a rare inherited skin disorder from a study of NLRP1 in two sisters with different severity of disease.
    Br J Dermatol. 2023;188:e18.
    >> Share


  630. A review of the role of four types of epidermal cells in messaging between the skin, nervous system and immune system.
    Br J Dermatol. 2023;188:e12.
    >> Share


  631. Patients successfully treated with baricitinib for atopic dermatitis: what happens if they lower their dose or stop treatment?
    Br J Dermatol. 2023;188:e14.
    >> Share

  632. REICH K, Simpson E, Wollenberg A, Bissonnette R, et al
    Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3.
    Br J Dermatol. 2023;188:208-217.
    >> Share

  633. KRUTMANN J, Piquero-Casals J, Morgado-Carrasco D, Granger C, et al
    Photoprotection for people with skin of colour: needs and strategies.
    Br J Dermatol. 2023;188:168-175.
    >> Share

  634. TALAGAS M
    Anatomical contacts between sensory neurons and epidermal cells: an unrecognized anatomical network for neuro-immuno-cutaneous crosstalk.
    Br J Dermatol. 2023;188:176-185.
    >> Share

  635. SHARMA A, Birnie AJ, Bordea C, Cheung ST, et al
    British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma in situ (Bowen disease) 2022.
    Br J Dermatol. 2023;188:186-194.
    >> Share

  636. KHAN SS, Ashcroft DM, Dlova N, Kini LC, et al
    A skin disease survey of the Maasai in North Eastern Tanzania.
    Br J Dermatol. 2023;188:303-304.
    >> Share

  637. ZAGONA-PRIZIO C, Khan S, Yee DK, Khan S, et al
    Psoriasis and fatigue: a cross-sectional population study of psoriasis patients in the United States using the Medical Expenditure Panel Surveys.
    Br J Dermatol. 2023;188:301-303.
    >> Share

  638. YANG DD, Borsky K, Jani C, Crowley C, et al
    Trends in keratinocyte skin cancer incidence, mortality and burden of disease in 33 countries between 1990 and 2017.
    Br J Dermatol. 2023;188:237-246.
    >> Share

  639. ADAMS L, Nakafero G, Grainge MJ, Card T, et al
    Is vaccination against COVID-19 associated with psoriasis or eczema flare? Self-controlled case series analysis using data from the Clinical Practice Research Datalink (Aurum).
    Br J Dermatol. 2023;188:297-299.
    >> Share

  640. LANGLEY RG, Sofen H, Dei-Cas I, Reich K, et al
    Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.
    Br J Dermatol. 2023;188:198-207.
    >> Share

  641. GILL K, Xu J, Kozera E, Stewart T, et al
    Strongyloides screening prior to dupilumab therapy in atopic dermatitis: a retrospective cohort study evaluating screening utility.
    Br J Dermatol. 2023;188:294-295.
    >> Share

  642. CARRASCOSA JM
    Conventional therapy in psoriasis. Lost in translation?
    Br J Dermatol. 2023 Feb 10:ljad030. doi: 10.1093.
    >> Share

  643. POIZEAU F, Balusson F, Lemaitre F, Tron C, et al
    The concomitant use of proton pump inhibitors and BRAF/MEK inhibitors in metastatic melanoma.
    Br J Dermatol. 2023 Feb 10:ljac085. doi: 10.1093.
    >> Share

  644. COWDELL F
    Living with hidradenitis suppurativa: managing the pain.
    Br J Dermatol. 2023;188:e10.
    >> Share


  645. Safety of baricitinib in adults with severe alopecia areata.
    Br J Dermatol. 2023;188:e15.
    >> Share


  646. Guidelines from the British Association of Dermatologists for the management of people with squamous cell carcinoma in situ (Bowen disease).
    Br J Dermatol. 2023;188:e13.
    >> Share


  647. Small particles of cobalt cause eczema in people with allergies.
    Br J Dermatol. 2023;188:e20.
    >> Share


  648. Merkel cell carcinoma: changes in the number of people affected, treatment and survival between 2004 and 2018.
    Br J Dermatol. 2023;188:e16.
    >> Share


  649. A review of the outcome measures used in clinical trials for vitiligo.
    Br J Dermatol. 2023;188:e17.
    >> Share

  650. MISTRY K, Levell NJ, Hollestein L, Wakkee M, et al
    Trends in incidence, treatment and survival of Merkel cell carcinoma in England 2004-2018: a cohort study.
    Br J Dermatol. 2023;188:228-236.
    >> Share

  651. GJERSVIK P
    Merkel cell carcinoma: aggressive, rare and on the rise.
    Br J Dermatol. 2023;188:162.
    >> Share

  652. KING B, Mostaghimi A, Shimomura Y, Zlotogorski A, et al
    Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials.
    Br J Dermatol. 2023;188:218-227.
    >> Share

  653. SMITH CM, Hambly R, Gatault S, Iglesias-Martinez LF, et al
    B-cell-derived transforming growth factor-beta may drive the activation of inflammatory macrophages and contribute to scarring in hidradenitis suppurativa.
    Br J Dermatol. 2023;188:290-310.
    >> Share

  654. SANZ J, Gao JL, King DS, Modest AM, et al
    Prevalence of rosacea in transgender and gender-diverse populations: a retrospective cohort study.
    Br J Dermatol. 2023;188:304-306.
    >> Share

  655. BISSONNETTE R
    Safety of baricitinib in patients with alopecia areata.
    Br J Dermatol. 2023;188:163.
    >> Share

  656. GOVENDER K, Sibanda W, Lenzy Y, Dlova NC, et al
    The efficacy of learning programmes on hairstylists and barbers in the early detection of alopecia and scalp disorders in South Africa.
    Br J Dermatol. 2023;188:308-309.
    >> Share

  657. STEELE L, Innes S, Oldham J, Cunningham M, et al
    Safety outcomes for topical corticosteroid use in eczema herpeticum: a single-centre retrospective cohort study.
    Br J Dermatol. 2023;188:295-297.
    >> Share

  658. ALHEGGI A, McGrath JA, Hubbard L, Greenblatt DT, et al
    Treatment of multifactorial anaemia in adults with severe epidermolysis bullosa using intravenous ferric carboxymaltose: a single institution, observational, retrospective study.
    Br J Dermatol. 2023;188:306-307.
    >> Share

  659. ELEFTHERIADOU V, Bergqvist C, Kechichian E, Shourick J, et al
    Has the core outcome (domain) set for vitiligo been implemented? An updated systematic review on outcomes and outcome measures in vitiligo randomized clinical trials.
    Br J Dermatol. 2023;188:247-258.
    >> Share

  660. BROWN-KORSAH JB, Omar D, Wang X, Taylor SC, et al
    Factors contributing to time to chemotherapy, immunotherapy and radiation for patients with mycosis fungoides in the United States National Cancer Database.
    Br J Dermatol. 2023;188:299-301.
    >> Share

  661. MCSWEENEY SM, Rayinda T, McGrath JA, Tziotzios C, et al
    Two phase III trials of baricitinib for alopecia areata: a critically appraised research paper.
    Br J Dermatol. 2023;188:195-197.
    >> Share

  662. CHEN ML, Rotemberg V, Lester JC, Novoa RA, et al
    Evaluation of diagnosis diversity in artificial intelligence datasets: a scoping review.
    Br J Dermatol. 2023;188:292-294.
    >> Share

  663. SYMANZIK C, John SM
    Occupational exposure to cobalt nanoparticles: potential implications on risk assessment and preventive measures.
    Br J Dermatol. 2023;188:161-162.
    >> Share

  664. BERKING C
    Update on the management of Bowen disease with a focus on patients' needs.
    Br J Dermatol. 2023;188:166.
    >> Share

  665. CHANPRAPAPH K, Seree-Aphinan C, Rattanakaemakorn P, Pomsoong C, et al
    A real-world prospective cohort study of immunogenicity and reactogenicity of ChAdOx1-S[recombinant] among patients with immune-mediated dermatological diseases.
    Br J Dermatol. 2023;188:268-277.
    >> Share

  666. BELLEFEUILLE G, Paiewonsky B, Khalid B, Freese RL, et al
    Inflammatory induration in hidradenitis suppurativa and application to severity assessment.
    Br J Dermatol. 2023;188:309-310.
    >> Share

  667. WU Y, Gu C, Wang S, Yin H, et al
    Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab.
    Br J Dermatol. 2023 Feb 9:ljad032. doi: 10.1093.
    >> Share

  668. BORGHI A, D'Abundo L, Bassi C, Lupini L, et al
    A microRNA signature to predict risk progression of vulvar lichen sclerosus to squamous cell carcinoma.
    Br J Dermatol. 2023 Feb 4:ljad024. doi: 10.1093.
    >> Share

    January 2023
  669. THORLACIUS L, Alam M
    A milestone reached for lichen sclerosus trial outcome standardisation.
    Br J Dermatol. 2023 Jan 27:ljad025. doi: 10.1093.
    >> Share

  670. MCSWEENEY SM, Bintcliffe K, Fassihi H, Sarkany R, et al
    Local cutaneous refractoriness to sun exposure following omalizumab injections in solar urticaria.
    Br J Dermatol. 2023 Jan 27:ljad012. doi: 10.1093.
    >> Share

  671. KVIST-HANSEN A, Perez-Alos L, Al-Sofi RF, Heftdal LD, et al
    Waning humoral and cellular immunity after COVID-19 vaccination in patients with psoriasis treated with methotrexate and biologics: a cohort study.
    Br J Dermatol. 2023 Jan 27:ljad023. doi: 10.1093.
    >> Share

  672. SIMPSON RC, Kirtschig G, Selk A, von Seitzberg S, et al
    Core outcome domains for lichen sclerosus: a CORALS initiative consensus statement.
    Br J Dermatol. 2023 Jan 26:ljac145. doi: 10.1093.
    >> Share

  673. SIMPSON RC
    Safety of tralokinumab in atopic dermatitis.
    Br J Dermatol. 2023 Jan 26:ljad007. doi: 10.1093.
    >> Share

  674. GROLLEAU C, Le Cleach L, Shourick J, Sbidian E, et al
    Long-term clinical trials of biologics in plaque psoriasis demonstrate heterogeneous study designs.
    Br J Dermatol. 2023 Jan 26:ljac142. doi: 10.1093.
    >> Share


  675. A new genetic cause for woolly hair and skin fragility.
    Br J Dermatol. 2023;188:e8.
    >> Share


  676. Clinical trial of Oleogel-S10 (birch bark extract gel) in epidermolysis bullosa.
    Br J Dermatol. 2023;188:e4.
    >> Share


  677. Lived experiences of patients with hidradenitis suppurativa-related pain.
    Br J Dermatol. 2023;188:e6.
    >> Share


  678. Providing new insights into the causes of large-to-giant congenital melanocytic naevi.
    Br J Dermatol. 2023;188:e7.
    >> Share

  679. KOGAME T, Yonekura S, Lovato P, Hirata M, et al
    Interleukin-13 inhibition by tralokinumab reduces inducible T-cell costimulator-positive innate lymphoid cells in skin lesions of atopic dermatitis.
    Br J Dermatol. 2023;188:146-148.
    >> Share

  680. STARK MS
    Deficiencies in mismatch DNA repair: providing the soil for large-to-giant congenital melanocytic naevus development.
    Br J Dermatol. 2023;188:5.
    >> Share

  681. BERTOLD C, Martel P, Passeron T, Bahadoran P, et al
    Pigmented demodicosis presenting as lentigo maligna diagnosed by reflectance confocal microscopy.
    Br J Dermatol. 2023;188:149-150.
    >> Share

  682. WANG H, Lin Z
    Identification of the underlying gene for Flegel disease: another 'two-hit' genodermatosis?
    Br J Dermatol. 2023;188:7-8.
    >> Share

  683. MELLERIO JE
    EASE-y does it: Oleogel-S10 for epidermolysis bullosa wounds.
    Br J Dermatol. 2023;188:10-11.
    >> Share

  684. OKUN MM
    The promise of personalized medicine for hidradenitis suppurativa.
    Br J Dermatol. 2023;188:3.
    >> Share

  685. JACKSON A, Moss C, Chandler KE, Balboa PL, et al
    Biallelic TUFT1 variants cause woolly hair, superficial skin fragility and desmosomal defects.
    Br J Dermatol. 2023;188:75-83.
    >> Share

  686. ORENSTEIN LAV, Salame N, Siira MR, Urbanski M, et al
    Pain experiences among those living with hidradenitis suppurativa: a qualitative study.
    Br J Dermatol. 2023;188:41-51.
    >> Share

  687. MOSS C, Roked F, Davis PJ, Khan M, et al
    Birth incidence and outcome of harlequin ichthyosis and collodion membrane in the UK and Ireland: a national 2-year prospective surveillance study.
    Br J Dermatol. 2023;188:139-140.
    >> Share

  688. KEARNEY N, Kirby B
    The devastating impact of hidradenitis suppurativa on employment.
    Br J Dermatol. 2023;188:9-10.
    >> Share

  689. THACI D, Vender R, de Rie MA, Conrad C, et al
    Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
    Br J Dermatol. 2023;188:22-31.
    >> Share

  690. MIRALI S, Yeung J
    Does bimekizumab stand the test of time for psoriasis?
    Br J Dermatol. 2023;188:5-6.
    >> Share

  691. SCHNEIDER-BURRUS S, Kalus S, Fritz B, Wolk K, et al
    The impact of hidradenitis suppurativa on professional life.
    Br J Dermatol. 2023;188:122-130.
    >> Share

  692. ZHANG J, Schuttelaar MLA
    Water and adult eczema: the hard truth?
    Br J Dermatol. 2023;188:e1.
    >> Share

  693. AUBERT H, Arlegui H, De Rycke Y, Bachelez H, et al
    Biologic tapering for patients with psoriasis with low disease activity: data from the French PsoBioTeq Registry.
    Br J Dermatol. 2023;188:150-152.
    >> Share

  694. WEI B, Gu J, Gao B, Bao Y, et al
    Deficient mismatch repair is detected in large-to-giant congenital melanocytic naevi: providing new insight into aetiology and diagnosis.
    Br J Dermatol. 2023;188:64-74.
    >> Share

  695. YUMICEBA V, Spielmann M
    When too much is too much: noncoding duplications in skin disorders.
    Br J Dermatol. 2023;188:e2-e3.
    >> Share

  696. JAGLE S, Hsu HH, Juratli HA, Zimmer AD, et al
    Pathogenic variants in the SPTLC1 gene cause hyperkeratosis lenticularis perstans.
    Br J Dermatol. 2023;188:94-99.
    >> Share

  697. BROWN AC, Earp EM, Veitch D, Wernham A, et al
    The top 10 research priorities for skin cancer surgery in the UK: results of a James Lind Alliance Priority Setting Partnership.
    Br J Dermatol. 2023;188:141-142.
    >> Share

  698. VINCENT R, Ormerod E, Gollins CE, Rai N, et al
    Semi-virtual patch testing: the future?
    Br J Dermatol. 2023;188:137-139.
    >> Share

  699. OYMANNS M, Daum-Marzian M, Bellm A, Elsayad K, et al
    Near complete responses to concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam radiation in advanced cutaneous T-cell lymphoma.
    Br J Dermatol. 2023;188:145-146.
    >> Share

  700. GABES M, Donhauser T, Kann G, Masur C, et al
    Burden of disease: assessing quality-of-life impacts in hyperhidrosis.
    Br J Dermatol. 2023;188:143-145.
    >> Share

  701. SHIONOYA A, Yoto Y, Hida T, Ishikawa A, et al
    Bacillus Calmette-Guerin-induced lupus vulgaris in a patient with Mendelian susceptibility to mycobacterial disease caused by a novel STAT1 variation.
    Br J Dermatol. 2023;188:142-143.
    >> Share

  702. HAMBLY R, Gatault S, Smith CM, Iglesias-Martinez LF, et al
    B-cell and complement signature in severe hidradenitis suppurativa that does not respond to adalimumab.
    Br J Dermatol. 2023;188:52-63.
    >> Share

  703. ZHOU L, Shao L, Gao S, Cui C, et al
    Impact of response patterns for patients with advanced acral melanoma treated with anti-programmed death-1 monotherapy.
    Br J Dermatol. 2023;188:112-121.
    >> Share

  704. CLARK A, Murphy MJ, King B, Cohen JM, et al
    Patient perspectives on the lived experience of granuloma annulare.
    Br J Dermatol. 2023;188:134-136.
    >> Share

  705. KRAKOWSKI I, Habel H, Nielsen K, Ingvar C, et al
    Association of metformin use and survival in patients with cutaneous melanoma and diabetes.
    Br J Dermatol. 2023;188:32-40.
    >> Share

  706. VAN EGMOND S, de Vere Hunt I, Cai ZR, Rizk N, et al
    The perspectives of 606 US dermatologists on active surveillance for low-risk basal cell carcinoma.
    Br J Dermatol. 2023;188:136-137.
    >> Share

  707. KERN JS, Sprecher E, Fernandez MF, Schauer F, et al
    Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study.
    Br J Dermatol. 2023;188:12-21.
    >> Share


  708. Patients with melanoma and diabetes benefit from metformin treatment.
    Br J Dermatol. 2023;188:e5.
    >> Share

  709. FISCHER J, Alter S
    Adding up the desmosomal genes causing syndromes with hair and skin involvement: identification of TUFT1 by state-of-the-art whole-genome sequencing.
    Br J Dermatol. 2023;188:8-9.
    >> Share

  710. ARDERN-JONES MR, Buchanan EE, Njungu S, O'Driscoll D, et al
    Successful Dose Reduction of Dupilumab in Atopic Dermatitis.
    Br J Dermatol. 2023 Jan 20:ljad011. doi: 10.1093.
    >> Share

  711. PADOVESE V, Fuller LC, Griffiths CEM, Maurer T, et al
    Migrant skin health - Perspectives from the Migrant Health Summit, Malta, 2022.
    Br J Dermatol. 2023 Jan 19:ljad001. doi: 10.1093.
    >> Share

  712. MAUL JT, Frohlich F, Maul LV, Stunnenberg R, et al
    Access to psoriasis treatment in Brazil and Chile: A cross-sectional multi-centre ;Global Healthcare Study on Psoriasis.
    Br J Dermatol. 2023 Jan 19:ljac128. doi: 10.1093.
    >> Share

  713. BRAVO FG
    Assessing the use of biologic therapy for psoriasis in Latin America.
    Br J Dermatol. 2023 Jan 13:ljad003. doi: 10.1093.
    >> Share

  714. FOSTIER W, Holt G, Sampson J, Rajan N, et al
    Folliculin inactivation and cutaneous leiomyosarcoma in Birt-Hogg-Dube syndrome.
    Br J Dermatol. 2023 Jan 11:ljac138. doi: 10.1093.
    >> Share

  715. SWIFT T
    Peristomal Skin Complications: New Materials Needed to Ease the Ostomy Care Market.
    Br J Dermatol. 2023 Jan 11:ljad006. doi: 10.1093.
    >> Share

  716. ALABAS OA, Mason KJ, Yiu ZZN, Hampton PJ, et al
    Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR.
    Br J Dermatol. 2023 Jan 6:ljad004. doi: 10.1093.
    >> Share

  717. YEW YW, Apfelbacher CJ
    Validation of novel diagnostic criteria for atopic dermatitis in an adult and elderly Chinese population.
    Br J Dermatol. 2023 Jan 5:ljac143. doi: 10.1093.
    >> Share

    December 2022
  718. QUIRKE-MCFARLANE S, Weinman J, Cook ES, Yiu ZZN, et al
    Non-adherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey.
    Br J Dermatol. 2022 Dec 23:ljac144. doi: 10.1093.
    >> Share

  719. SO C, McCarthy D, Watts CG, Kearney C, et al
    Diagnostic biopsies of suspected skin cancer in general practice from 2010 to 2017 in Victoria, Australia.
    Br J Dermatol. 2022 Dec 22:ljac111. doi: 10.1093.
    >> Share

  720. CICHY J
    Compartmentalized response of the human epidermis to staphylococci.
    Br J Dermatol. 2022 Dec 21:ljac125. doi: 10.1093.
    >> Share

  721. VEGAS LP, Claudepierre P
    Trajectories of comorbidities in patients with psoriasis: a question to be answered.
    Br J Dermatol. 2022 Dec 21:ljac126. doi: 10.1093.
    >> Share

  722. PERRIER F, Robsahm TE, Ghiasvand R, Borch KB, et al
    No association between physical activity and primary melanoma thickness in a cohort of Norwegian women.
    Br J Dermatol. 2022 Dec 21:ljac136. doi: 10.1093.
    >> Share

  723. LAN J, Huang Q, Yang L, Li Y, et al
    Effects of ambient air pollution on outpatient visits for psoriasis in Wuhan, China: a time-series analysis.
    Br J Dermatol. 2022 Dec 19:ljac124. doi: 10.1093.
    >> Share

  724. ADESANYA EI, Matthewman J, Schonmann Y, Hayes JF, et al
    Factors associated with depression, anxiety and severe mental illness among adults with atopic eczema or psoriasis: a systematic review and meta-analysis.
    Br J Dermatol. 2022 Dec 19:ljac132. doi: 10.1093.
    >> Share

  725. HUGHES O, Shelton KH, Penny H, Thompson AR, et al
    Parent and child experience of skin conditions: Relevance for the provision of mindfulness-based interventions.
    Br J Dermatol. 2022 Dec 15:ljac129. doi: 10.1093.
    >> Share

  726. KEZIC S, van der Molen HF
    Occupational skin cancer: measurements of ultraviolet radiation exposure bring knowledge for prevention.
    Br J Dermatol. 2022 Dec 14:ljac127. doi: 10.1093.
    >> Share

  727. YUE W, Cheng D, Sun Z, Shen Y, et al
    Validation of diagnostic criteria for atopic dermatitis and proposal of novel diagnostic criteria for adult and elderly Chinese populations: a multicentre, prospective, clinical setting-based study.
    Br J Dermatol. 2022 Dec 12:ljac097. doi: 10.1093.
    >> Share

  728. SAETRE R, Gotfredsen JL, Nonboe P, Hansen HD, et al
    An ostomy baseplate with a skin-protection technology reduces peristomal skin complications: a randomized controlled trial (the ATTRACT study).
    Br J Dermatol. 2022 Dec 8:ljac122. doi: 10.1093.
    >> Share

  729. FLOHR C
    How we treat atopic dermatitis now and how that will change over the next 5 years.
    Br J Dermatol. 2022 Dec 7:ljac116. doi: 10.1093.
    >> Share

  730. PLATAIS C, Lalagianni N, Momen S, Ormond M, et al
    Efficacy of hydroxychloroquine in oral lichen planus: a retrospective review.
    Br J Dermatol. 2022 Dec 3:ljac113. doi: 10.1093.
    >> Share

  731. MROWIETZ U, Augustin M
    Using the upgrade criteria of the European Psoriasis Consensus is best practice care according to the people-centred healthcare concept of the World Health Organization.
    Br J Dermatol. 2022;187:1007-1008.
    >> Share


  732. A review of how pain is measured in painful skin conditions and rheumatoid arthritis studies, to determine pain measurement in future hidradenitis suppurativa trials.
    Br J Dermatol. 2022;187:e196-e221.
    >> Share

  733. PHILPOTT M
    Transcriptomic analysis identifies regulators of the Wnt signalling and hypoxia-inducible factor pathways as possible mediators of androgenetic alopecia.
    Br J Dermatol. 2022;187:845.
    >> Share

  734. LAX SJ, Drucker AM
    How will brepocitinib cream compare with established treatments for mild-to-moderate eczema?
    Br J Dermatol. 2022;187:838.
    >> Share

  735. KRIDIN K, Hammers CM
    Atypical clinical manifestation and protracted latency are observed in the emerging variant of checkpoint inhibitor-associated bullous pemphigoid.
    Br J Dermatol. 2022;187:843-844.
    >> Share

  736. EDEN M, Hainsworth R, Gordon LG, Epton T, et al
    On the potential beneficial effects of indoor tanning: reply from the authors.
    Br J Dermatol. 2022;187:1057-1058.
    >> Share

  737. MIDGETTE B, Strunk A, Akilov O, Alavi A, et al
    Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project.
    Br J Dermatol. 2022;187:927-935.
    >> Share

  738. CAPOZZA K, Vastrup A, Proctor A, Roberts A, et al
    The sound of silence: where are the voices of patients in eczema guideline development?
    Br J Dermatol. 2022;187:1005-1006.
    >> Share

  739. REHMAN R, Haque M, Ceresnie M, Hamzavi IH, et al
    Dermatological considerations and culturally sensitive recommendations for women who wear the hijab.
    Br J Dermatol. 2022;187:1003-1004.
    >> Share

  740. LIU J, Chen Z, Hu L, Song Z, et al
    Three new founder mutations in Chinese patients with Nagashima-type palmoplantar keratoderma.
    Br J Dermatol. 2022;187:1043-1045.
    >> Share

  741. VERMEER MCSC, Al-Shinnag M, Sillje HHW, Gaytan AE, et al
    A translation re-initiation variant in KLHL24 also causes epidermolysis bullosa simplex and dilated cardiomyopathy via intermediate filament degradation.
    Br J Dermatol. 2022;187:1045-1048.
    >> Share

  742. SILVERTHORNE CA, Bowen C, Lord J, McHugh N, et al
    A qualitative study of patients' experiences of screening for psoriatic arthritis.
    Br J Dermatol. 2022;187:1035-1037.
    >> Share

  743. LINDQVIST PG, Epstein E, Landin-Olsson M
    On the potential beneficial effects of indoor tanning.
    Br J Dermatol. 2022;187:1057.
    >> Share

  744. MOSTMANS Y, Smith V, Cutolo M, Melsens K, et al
    Nailfold videocapillaroscopy and serum vascular endothelial growth factor in probable COVID-19-induced chilblains: a cross-sectional study to assess microvascular impairment.
    Br J Dermatol. 2022;187:1017-1019.
    >> Share

  745. MATARD B, Bourrat E, Cavalie M, Chiaverini C, et al
    Folliculitis decalvans and dystrophic epidermolysis bullosa: a significant association.
    Br J Dermatol. 2022;187:1026-1028.
    >> Share

  746. JI-XU A, Lei DK, Worswick S, Maloney NJ, et al
    Patient and disease characteristics associated with psychiatric symptoms and impaired quality of life in pityriasis rubra pilaris.
    Br J Dermatol. 2022;187:1024-1026.
    >> Share

  747. KOPTYEV J, Strunk A, Garg A
    Low predictive value of questionnaire-based diagnosis of hidradenitis suppurativa.
    Br J Dermatol. 2022;187:1015-1017.
    >> Share

  748. COOK MK, Perche PO, White JC, Feldman SR, et al
    Psychosocial burden of frontal fibrosing alopecia: a qualitative interview study.
    Br J Dermatol. 2022;187:1013-1015.
    >> Share

  749. LIU Q, Tang Y, Huang Y, Wang J, et al
    Insights into male androgenetic alopecia using comparative transcriptome profiling: hypoxia-inducible factor-1 and Wnt/beta-catenin signalling pathways.
    Br J Dermatol. 2022;187:936-947.
    >> Share

  750. GABES M, Ragamin A, Baker A, Kann G, et al
    Content validity of the Recap of atopic eczema (RECAP) instrument in Dutch, English and German to measure eczema control in young people with atopic eczema: a cognitive interview study.
    Br J Dermatol. 2022;187:919-926.
    >> Share

    November 2022
  751. HU C, Jansen PW
    Do adolescents with atopic dermatitis have lower cognitive function and school performance than their peers without atopic dermatitis?
    Br J Dermatol. 2022 Nov 29:ljac105. doi: 10.1093.
    >> Share

  752. KOKOLAKIS G, Warren RB, Strober B, Blauvelt A, et al
    Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
    Br J Dermatol. 2022 Nov 29:ljac089. doi: 10.1093.
    >> Share

  753. ABUABARA K, Langan SM
    Atopic dermatitis across the life course.
    Br J Dermatol. 2022 Nov 18:ljac072. doi: 10.1093.
    >> Share

  754. TRIER AM, Kim BS
    Insights into atopic dermatitis pathogenesis lead to newly approved systemic therapies.
    Br J Dermatol. 2022 Nov 18:ljac016. doi: 10.1093.
    >> Share

  755. CLAYTON K, Holbrook DJ, Vallejo A, Porter G, et al
    Skin programming of inflammatory responses to Staphylococcus aureus is compartmentalized according to epidermal keratinocyte differentiation status.
    Br J Dermatol. 2022 Nov 17:ljac088. doi: 10.1093.
    >> Share

  756. SCHELL SL, Cong Z, Sennett ML, Gettle SL, et al
    Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies.
    Br J Dermatol. 2022 Nov 17:ljac096. doi: 10.1093.
    >> Share

  757. IBRAHIM N, Jovic M, Ali S, Williams N, et al
    The epidemiology, healthcare and societal burden of basal cell carcinoma in Wales 2000-2018: a retrospective nationwide analysis.
    Br J Dermatol. 2022 Nov 17:ljac090. doi: 10.1093.
    >> Share

  758. WEISSHAAR E, Bentz P, Haufe E, Heinrich L, et al
    Itching and treatments in atopic dermatitis (AD): results from the German AD registry TREATgermany.
    Br J Dermatol. 2022 Nov 17:ljac070. doi: 10.1093.
    >> Share

  759. GRINNELL M, Concha J, Feng R, Keyes E, et al
    Clinical research: photo validation study using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) scores in patients with dermatomyositis.
    Br J Dermatol. 2022 Nov 17:ljac091. doi: 10.1093.
    >> Share

  760. ROSENO NAL, Lorup EH, Richardson C, Alarcon I, et al
    Exploring disease comorbidities and temporal disease progression of psoriasis: an observational, retrospective, multi-database, cohort study.
    Br J Dermatol. 2022 Nov 11:ljac086. doi: 10.1093.
    >> Share

  761. WITTLICH M, Westerhausen S, Strehl B, Versteeg H, et al
    The GENESIS-UV study on ultraviolet radiation exposure levels in 250 occupations to foster epidemiological and legislative efforts to combat nonmelanoma skin cancer.
    Br J Dermatol. 2022 Nov 11:ljac093. doi: 10.1093.
    >> Share

  762. HE X, Shi H
    How does acral melanoma respond to immunotherapy?
    Br J Dermatol. 2022 Nov 10:ljac035. doi: 10.1093.
    >> Share

  763. VITTRUP I, Andersen YMF, Skov L, Wu JJ, et al
    The association between atopic dermatitis, cognitive function and school performance in children and young adults.
    Br J Dermatol. 2022 Nov 3:ljac058. doi: 10.1093.
    >> Share


  764. Measuring the effects of treatments for capillary malformations (vascular birthmarks).
    Br J Dermatol. 2022;187:e173-e192.
    >> Share

  765. EVRENOGLOU T
    Stratification according to disease severity can better reveal the relative effectiveness of treatments for acne vulgaris.
    Br J Dermatol. 2022;187:637-638.
    >> Share

  766. FLEDDERUS AC, Gout HA
    A core outcome set for pressure ulcers: an important step towards standardized outcome reporting of prevention strategies.
    Br J Dermatol. 2022;187:634-635.
    >> Share

  767. FROELUNDE AS, Vestergaard C
    Prurigo nodularis: the epidemiology of an under-recognized disease.
    Br J Dermatol. 2022;187:e171-e172.
    >> Share

  768. GIAMARELLOS-BOURBOULIS EJ
    Modulation of keratin deposition and pathogenesis of hidradenitis suppurativa: evidence coming from pachyonychia congenita.
    Br J Dermatol. 2022;187:e170-e171.
    >> Share

  769. ORCHARD D
    Preventing atopic eczema: vitamin D supplementation another piece of the puzzle?
    Br J Dermatol. 2022;187:630-631.
    >> Share

  770. HARRS C, van den Akker PC, Baardman R, Duipmans JC, et al
    The aggressive behaviour of squamous cell carcinoma in epidermolysis bullosa: analysis of clinical outcomes and tumour characteristics in the Dutch EB Registry.
    Br J Dermatol. 2022;187:824-826.
    >> Share

  771. CHOSIDOW O, Beylot-Barry M, Corgibet F, Jouan N, et al
    Isotretinoin: reasserting its public health value at the population level, addressing potential neuropsychiatric risk at the individual level.
    Br J Dermatol. 2022;187:831-832.
    >> Share

  772. LOPEZ DJ, Singh A, Waidyatillake NT, Su JC, et al
    The association between domestic hard water and eczema in adults from the UK Biobank cohort study.
    Br J Dermatol. 2022;187:704-712.
    >> Share

  773. MALOVITSKI K, Meijers O, Cohen-Barak E, Bergman J, et al
    Heterozygous variants in the integrin subunit beta 4 gene (ITGB4) cause autosomal dominant nail dystrophy.
    Br J Dermatol. 2022;187:826-828.
    >> Share

  774. BONTOUX C, de Masson A, Thonnart N, Ram-Wolff C, et al
    Large-cell transformation is an independent poor prognostic factor in Sezary syndrome: analysis of 117 cases.
    Br J Dermatol. 2022;187:815-817.
    >> Share

  775. RING HC, Egeberg A, Zachariae C, Thomsen SF, et al
    Considerable improvement in hidradenitis suppurativa with oral roflumilast therapy.
    Br J Dermatol. 2022;187:813-815.
    >> Share

  776. MAVRANEZOULI I, Daly CH, Welton NJ, Deshpande S, et al
    A systematic review and network meta-analysis of topical pharmacological, oral pharmacological, physical and combined treatments for acne vulgaris.
    Br J Dermatol. 2022;187:639-649.
    >> Share

  777. ALI S, Pham H, Waterhouse M, Baxter C, et al
    The effect of vitamin D supplementation on risk of keratinocyte cancer: an exploratory analysis of the D-Health randomized controlled trial.
    Br J Dermatol. 2022;187:667-675.
    >> Share

  778. LECHNER A, Coleman S, Balzer K, Kirkham JJ, et al
    Core outcomes for pressure ulcer prevention trials: results of an international consensus study: Classification: Outcomes and qualitative research.
    Br J Dermatol. 2022;187:743-752.
    >> Share

  779. MARANGA A, Roche FC, Alausa M, McWilliams T, et al
    Quality of life in patients with central centrifugal cicatricial alopecia: a preliminary study.
    Br J Dermatol. 2022;187:802-804.
    >> Share

  780. BATAILLE P, Layese R, Claudepierre P, Paris N, et al
    Paradoxical reactions and biologic agents: a French cohort study of 9303 patients.
    Br J Dermatol. 2022;187:676-683.
    >> Share

  781. EL-HEIS S, D'Angelo S, Curtis EM, Healy E, et al
    Maternal antenatal vitamin D supplementation and offspring risk of atopic eczema in the first 4 years of life: evidence from a randomized controlled trial.
    Br J Dermatol. 2022;187:659-666.
    >> Share

  782. GREENBLATT DT, Hubbard L, Bloor C, Card D, et al
    Vitamin C concentrations in patients with epidermolysis bullosa.
    Br J Dermatol. 2022;187:808-810.
    >> Share

  783. HUGHES O
    The need for psychological support in routine dermatological care across the UK.
    Br J Dermatol. 2022;187:778-779.
    >> Share

  784. GAMBICHLER T, Abu Rached N, Susok L, Becker JC, et al
    Serum neuron-specific enolase independently predicts outcomes of patients with Merkel cell carcinoma.
    Br J Dermatol. 2022;187:806-808.
    >> Share

  785. SARASWAT N, Kumar S, Tripathy DM, Gopal MM, et al
    COVID-19-associated necrolytic acral erythema with postvaccination exacerbation in a seronegative patient.
    Br J Dermatol. 2022;187:e169.
    >> Share

  786. BOUDREAUX BW, Pincelli TP, Bhullar PK, Patel MH, et al
    Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis.
    Br J Dermatol. 2022;187:650-658.
    >> Share

  787. SANGHVI AP, Miles JA, Sayed C
    Clostridium difficile infection risk in patients with hidradenitis suppurativa.
    Br J Dermatol. 2022;187:800-802.
    >> Share

  788. MERVIS JS, Maeng MM, Kirsner RS, Wester ST, et al
    Teprotumumab as a novel treatment for pretibial myxoedema.
    Br J Dermatol. 2022;187:795-797.
    >> Share

  789. SINGH R, Balogh EA, Senthilnathan A, Richardson IM, et al
    Fear of negative evaluation in patients with hidradenitis suppurativa is correlated with worse quality of life: an observational study.
    Br J Dermatol. 2022;187:788-790.
    >> Share

  790. BONDS PD, Huang J, Ike J, Mukherjee E, et al
    International Classification of Diseases codes do not capture all cases of hidradenitis suppurativa in the electronic health record: a retrospective cohort.
    Br J Dermatol. 2022;187:787-788.
    >> Share

  791. BELZER A, Silber A, Mehra S, Gilani S, et al
    Mucosal haemangioma in the setting of treatment with trastuzumab emtansine (T-DM1).
    Br J Dermatol. 2022;187:e168.
    >> Share

  792. LEWITT TM, Mammis-Gierbolini A, Parnell M, Sarfo A, et al
    International consensus definition of disease flare in hidradenitis suppurativa.
    Br J Dermatol. 2022;187:785-787.
    >> Share

    October 2022
  793. MIDANDER K, Werner P, Isaksson M, Wisgrill L, et al
    Cobalt nanoparticles cause allergic contact dermatitis in humans.
    Br J Dermatol. 2022 Oct 28:ljac043. doi: 10.1093.
    >> Share

  794. TURNER CT, Zeglinski MR, Boivin W, Zhao H, et al
    Granzyme K contributes to endothelial microvascular damage and leakage during skin inflammation.
    Br J Dermatol. 2022 Oct 23:ljac017. doi: 10.1093.
    >> Share

  795. ALI F, Smith CH, Mahil SK
    Spesolimab in the treatment of generalized pustular psoriasis: a critically appraised research paper.
    Br J Dermatol. 2022 Oct 23:ljac049. doi: 10.1093.
    >> Share

  796. YOTSU RR, Fuller LC, Murdoch ME, Revankar C, et al
    World Health Organization strategic framework for integrated control and management of skin-related neglected tropical diseases: what does this mean for dermatologists?
    Br J Dermatol. 2022 Oct 20:ljac031. doi: 10.1093.
    >> Share


  797. The search for measurable predictors linked with negative health complications in psoriasis.
    Br J Dermatol. 2022;187:e158-e167.
    >> Share

  798. TZELLOS T
    Implementing evidence-based strategies to optimize the journey of patients with hidradenitis suppurativa.
    Br J Dermatol. 2022;187:462-463.
    >> Share

  799. PANDYA AG, Ezzedine K
    Noticeability of vitiligo is in the eye of the beholder.
    Br J Dermatol. 2022;187:461-462.
    >> Share

  800. DESSINIOTI C
    Advances in acne clinical research: a new class of topical treatment for moderate-to-severe facial acne.
    Br J Dermatol. 2022;187:455-456.
    >> Share

  801. CUCKA B, Biglione B, Zhou L, Phillips EJ, et al
    Drug reaction with eosinophilia and systemic symptoms in patients hospitalized with COVID-19: a case series from a large US healthcare system.
    Br J Dermatol. 2022;187:619-622.
    >> Share

  802. MISERY L
    Chronic prurigo.
    Br J Dermatol. 2022;187:464-471.
    >> Share

  803. RENERT-YUVAL Y, Correa da Rosa J, Garcet S, Pavel AB, et al
    Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes.
    Br J Dermatol. 2022;187:539-547.
    >> Share

  804. DARRIGADE AS, Oules B, Sohier P, Jullie ML, et al
    Sweet-like syndrome and multiple COVID arm syndrome following COVID-19 vaccines: 'specific' patterns in a series of 192 patients.
    Br J Dermatol. 2022;187:615-617.
    >> Share

  805. POTTIER C, Eymieux S, Blanchard-Laumonnier E, Robert J, et al
    Loose anagen hair syndrome: take a closer look!
    Br J Dermatol. 2022;187:e156.
    >> Share

  806. YUKSEL YT, Edslev SM, Janstrup AK, Goldeman MS, et al
    Colonization with Staphylococcus aureus in healthcare workers: consequences of hand eczema.
    Br J Dermatol. 2022;187:609-611.
    >> Share

  807. TAYLOR MT, Bordeaux ZA, Deng J, Parthasarathy V, et al
    Association between prurigo nodularis and substance use disorders.
    Br J Dermatol. 2022;187:608-609.
    >> Share

  808. RING HC, Yao Y, Maul JT, Ingram JR, et al
    The road to biologics in patients with hidradenitis suppurativa: a nationwide drug utilization study.
    Br J Dermatol. 2022;187:523-530.
    >> Share

  809. BATCHELOR JM, Gran S, Leighton P, Howells L, et al
    Using the Vitiligo Noticeability Scale in clinical trials: construct validity, interpretability, reliability and acceptability.
    Br J Dermatol. 2022;187:548-556.
    >> Share

  810. DANIEL SR, Gandhi K, Anastassopoulos KP, Pandya AG, et al
    Impact of nonsegmental vitiligo on patients' health-related quality of life in the United States.
    Br J Dermatol. 2022;187:603-606.
    >> Share

  811. KLEIN EJ, Shapiro J, Piraccini B, Cummins D, et al
    Giving a voice: dermatologists' legislative advocacy for patients with hair loss.
    Br J Dermatol. 2022;187:582-583.
    >> Share

  812. PICARDO M, Cardinali C, La Placa M, Lewartowska-Bialek A, et al
    Efficacy and safety of N-acetyl-GED-0507-34-LEVO gel in patients with moderate-to severe facial acne vulgaris: a phase IIb randomized double-blind, vehicle-controlled trial.
    Br J Dermatol. 2022;187:507-514.
    >> Share

  813. HAGAN PG, Bouazzi D, Nyarko G, Dartey ES, et al
    Prevalence of Hidradenitis Suppurativa in Berekum, Ghana.
    Br J Dermatol. 2022;187:586-587.
    >> Share

    September 2022
  814. GRAU-PEREZ M, Garcia-Doval I
    Differences in cutaneous manifestations of COVID-19 during the Delta and Omicron waves revealed using the ZOE app.
    Br J Dermatol. 2022 Sep 23. doi: 10.1111/bjd.21868.
    >> Share

  815. SIMPSON EL, Merola JF, Silverberg JI, Reich K, et al
    Safety of Tralokinumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-blind, Placebo-controlled Phase 2 and Phase 3 Trials.
    Br J Dermatol. 2022 Sep 9. doi: 10.1111/bjd.21867.
    >> Share

  816. PUIG L
    Psoriasis treatment: no more room on the summit?
    Br J Dermatol. 2022 Sep 5. doi: 10.1111/bjd.21848.
    >> Share

  817. KIM RW, Barta K, Begolka WS, Capozza K, et al
    The quantitative impact of atopic dermatitis on caregivers across multiple life domains.
    Br J Dermatol. 2022 Sep 3. doi: 10.1111/bjd.21855.
    >> Share

  818. SIVALINGAM V, Tamber K
    Understanding the impact of life with vulval lichen sclerosus.
    Br J Dermatol. 2022 Sep 2. doi: 10.1111/bjd.21846.
    >> Share

  819. LEE H, Kwon O
    Immune checkpoint inhibitor-induced cutaneous toxicities: they are not just random.
    Br J Dermatol. 2022 Sep 2. doi: 10.1111/bjd.21838.
    >> Share


  820. Revolutionizing Atopic Dermatitis, 9-11 April 2022.
    Br J Dermatol. 2022;187:e80-e155.
    >> Share

  821. WILSON BN, Shah R, Menzer C, Aleisa A, et al
    Consensus on the Clinical Management of Chronic Radiation Dermatitis and Radiation Fibrosis: A Delphi Survey.
    Br J Dermatol. 2022 Sep 1. doi: 10.1111/bjd.21852.
    >> Share

  822. APFELBACHER C
    Closing a gap: an investigator global assessment for use in hidradenitis suppurativa clinical trials.
    Br J Dermatol. 2022;187:e79.
    >> Share

  823. PAVLOVSKY M, Peled A, Sarig O, Astman N, et al
    Coexistence of pachyonychia congenita and hidradenitis suppurativa: more than a coincidence.
    Br J Dermatol. 2022;187:392-400.
    >> Share

  824. GOULDEN V, Ling TC, Babakinejad P, Dawe R, et al
    British Association of Dermatologists and British Photodermatology Group guidelines for narrowband ultraviolet B phototherapy 2022.
    Br J Dermatol. 2022;187:295-308.
    >> Share

  825. AARTS P, van der Zee HH
    Damage in hidradenitis suppurativa: receiving the deserved attention.
    Br J Dermatol. 2022;187:282-283.
    >> Share

  826. FAZEL S, Paljarvi T
    Response to 'Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data': reply from authors.
    Br J Dermatol. 2022;187:450-451.
    >> Share

  827. CHANG R, Lai CC, Hung YM, Wang SI, et al
    Response to 'Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data'.
    Br J Dermatol. 2022;187:450.
    >> Share

  828. GARG A, Krueger JG
    Raising the bar for efficacy in hidradenitis suppurativa: a rationale for combination targeted therapies.
    Br J Dermatol. 2022;187:414-415.
    >> Share

  829. DI CESARE A, Nikolakis G, Kanni T, Giamarellos-Bourboulis EJ, et al
    Identification of clinical features affecting diagnostic delay in paediatric hidradenitis suppurativa: results from a multicentre observational study.
    Br J Dermatol. 2022;187:428-430.
    >> Share

  830. PENNITZ A, Kinberger M, Avila Valle G, Passeron T, et al
    Self-applied topical interventions for melasma: a systematic review and meta-analysis of data from randomized, investigator-blinded clinical trials.
    Br J Dermatol. 2022;187:309-317.
    >> Share

  831. MERHI R, Canu D, Barnetche T, Duchez E, et al
    Assessment of Vitiligo Area Scoring Index (VASI), Facial-VASI and Vitiligo Extent Score using standardized photography of patients with vitiligo.
    Br J Dermatol. 2022;187:422-424.
    >> Share

  832. KLEIN B, Treudler R, Dumann K, Boldt A, et al
    Clinical response of CARD14-associated papulosquamous eruption to an anti-interleukin-17A antibody.
    Br J Dermatol. 2022;187:419-422.
    >> Share

  833. GRINNELL M, Keyes E, Diaz D, Vazquez T, et al
    Mycophenolate mofetil and methotrexate efficacy in dermatomyositis.
    Br J Dermatol. 2022;187:437-438.
    >> Share

  834. JIANG SW, Kwock JT, Liu B, Petty AJ, et al
    High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa.
    Br J Dermatol. 2022;187:417-419.
    >> Share

  835. CHEN F, Deng D, Pan C, Yao Z, et al
    Detection and characterization of low-level mosaicism among clinically unaffected parents of 'sporadic' epidermolysis bullosa simplex cases.
    Br J Dermatol. 2022;187:441-443.
    >> Share

  836. FRITSCHE M, Okun M, Kirby JS
    Damage in hidradenitis suppurativa: a narrative review emphasizing the need for a novel outcome measure.
    Br J Dermatol. 2022;187:288-294.
    >> Share

  837. HASAN ZU, Ahmed I, Matin RN, Homer V, et al
    Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments).
    Br J Dermatol. 2022;187:324-337.
    >> Share

    August 2022
  838. KEMPF W
    Follicular T helper cells and cutaneous T-cell lymphomas.
    Br J Dermatol. 2022 Aug 31. doi: 10.1111/bjd.21839.
    >> Share

  839. MOLHO-PESSACH V, Hartshtark S, Merims S, Lotem M, et al
    Giant congenital melanocytic nevus with a novel CUX1-BRAF fusion mutation treated with trametinib.
    Br J Dermatol. 2022 Aug 28. doi: 10.1111/bjd.21851.
    >> Share

  840. BALAK DMW, Rissmann R
    Anti-interleukin-17A for pityriasis rubra pilaris: catching the psoriasis biologic wave.
    Br J Dermatol. 2022 Aug 22. doi: 10.1111/bjd.21813.
    >> Share

  841. NALDI L, Cazzaniga S
    The chicken or the egg: disentangling the relationship between smoking, alcohol consumption and psoriasis using Mendelian randomization.
    Br J Dermatol. 2022 Aug 21. doi: 10.1111/bjd.21805.
    >> Share

  842. LIU Y, Banka S, Huang Y, Hardman-Smart J, et al
    Germline intergenic duplications at Xq26.1 underlie Bazex-Dupre-Christol basal cell carcinoma susceptibility syndrome.
    Br J Dermatol. 2022 Aug 20. doi: 10.1111/bjd.21842.
    >> Share

  843. LANDIS MN, Arya M, Smith S, Draelos Z, et al
    Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomised, double-blind, vehicle-controlled, dose-ranging, and parallel-group study.
    Br J Dermatol. 2022 Aug 20. doi: 10.1111/bjd.21826.
    >> Share

  844. KAWSAR A, Edwards C, Patel P, Heywood RM, et al
    Checkpoint inhibitor associated bullous cutaneous immune related adverse events: a multi-centre observational study.
    Br J Dermatol. 2022 Aug 17. doi: 10.1111/bjd.21836.
    >> Share

  845. LEVIN NA, Rashighi M
    Psoriasis and hidradenitis suppurativa are associated with inflammatory bowel disease: a growing body of evidence.
    Br J Dermatol. 2022 Aug 17. doi: 10.1111/bjd.21808.
    >> Share

  846. MCCOY K, DeSimone J
    Progression of in situ and early invasive cutaneous squamous cell carcinomas concurrent with successful target tumor response to PD-1 inhibitor.
    Br J Dermatol. 2022 Aug 17. doi: 10.1111/bjd.21831.
    >> Share

  847. CHRISTIANSEN AG, Carstensen O, Sommerlund M, Clausen PA, et al
    Prevalence of skin sensitisation and dermatitis among epoxy-exposed workers in the wind turbine industry.
    Br J Dermatol. 2022 Aug 16. doi: 10.1111/bjd.21830.
    >> Share

  848. KIM RW, Barta K, Begolka WS, Capozza K, et al
    Qualitative analysis of the impact of atopic dermatitis on caregivers and the quantitative impact of atopic dermatitis on caregivers across multiple life domains.
    Br J Dermatol. 2022 Aug 16. doi: 10.1111/bjd.21828.
    >> Share

  849. HASAN SB, Gendra R, James J, Morris D, et al
    Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: A scoping review to inform pain measurement in hidradenitis suppurativa.
    Br J Dermatol. 2022 Aug 12. doi: 10.1111/bjd.21821.
    >> Share

  850. RANUM A, Freese R, Ramesh V, Pearson DR, et al
    Lichen sclerosus in female patients is associated with an increased risk of metabolic syndrome and cardiovascular comorbidities: A retrospective cohort review.
    Br J Dermatol. 2022 Aug 10. doi: 10.1111/bjd.21811.
    >> Share

  851. BELL KJL, Nijsten T
    Melanoma overdiagnosis: why it matters and what can be done about it.
    Br J Dermatol. 2022 Aug 5. doi: 10.1111/bjd.21750.
    >> Share

  852. CATALA A, Clavo Escribano P, Riera J, Martin-Ezquerra G, et al
    Monkeypox outbreak in Spain: clinical and epidemiological findings in a prospective cross-sectional study of 185 cases.
    Br J Dermatol. 2022 Aug 2. doi: 10.1111/bjd.21790.
    >> Share

  853. FENG Y, Lu Y, Wang H
    Leucoderma secondary to wig wearing.
    Br J Dermatol. 2022;187:e64.
    >> Share


  854. Better understanding about the severity of disease in cutaneous T-cell lymphoma from studying immune checkpoint receptors.
    Br J Dermatol. 2022;187:e69-e76.
    >> Share

  855. GARG A, Zema C, Kim K, Gao W, et al
    Development and initial validation of the HS-IGA: a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trials.
    Br J Dermatol. 2022;187:203-210.
    >> Share

  856. BIRABAHARAN M, Kaelber DC, Orme CM, Paravar T, et al
    Evaluating risk of bullous pemphigoid after mRNA COVID-19 vaccination.
    Br J Dermatol. 2022;187:271-273.
    >> Share

  857. LIU Y, Tan Y, Liu J, Song Z, et al
    Novel and founder variants of SERPINA12 in Chinese patients with autosomal recessive palmoplantar keratoderma.
    Br J Dermatol. 2022;187:267-270.
    >> Share

  858. DI RAIMONDO C, Rubio-Gonzalez B, Palmer J, Weisenburger DD, et al
    Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and Sezary syndrome: association with disease stage and clinical outcome.
    Br J Dermatol. 2022;187:234-243.
    >> Share

  859. JIANG TT, Kruglov O, Geskin L, Akilov OE, et al
    Repetitive expanded T-cell receptor clonotypes impart the classic T helper 2 Sezary cell phenotype.
    Br J Dermatol. 2022;187:265-267.
    >> Share

  860. BAE JM, Kim M, Han JH, Lee S, et al
    Preventive effect of levodopa on vitiligo development: a nationwide case-control study.
    Br J Dermatol. 2022;187:259-261.
    >> Share

  861. RING HC, Thomsen SF
    The impact of Janus kinase 1 inhibitors on quality of life in patients with hidradenitis suppurativa.
    Br J Dermatol. 2022;187:274.
    >> Share

  862. YUKSEL YT, Ibler K, Agner T, Ofenloch R, et al
    Validation of the Danish version of the Quality of Life in Hand Eczema Questionnaire (QOLHEQ).
    Br J Dermatol. 2022;187:256-258.
    >> Share

  863. DE VERE HUNT I, Halley M, Sum K, Yekrang K, et al
    A qualitative exploration of the experiences of itch for adults living with epidermolysis bullosa.
    Br J Dermatol. 2022;187:261-263.
    >> Share

  864. BUECHLER CR, Sagher E, Tisack A, Jacobsen G, et al
    Demographic factors and disparate outcomes in mycosis fungoides: retrospective analysis of a racially diverse 440-patient cohort from Detroit, Michigan, USA.
    Br J Dermatol. 2022;187:246-248.
    >> Share

  865. SINGH R, Mohammed A, Senthilnathan A, Feldman SR, et al
    Hidradenitis suppurativa may impact clothing patterns even in patients with mild disease and symptoms: an observational study.
    Br J Dermatol. 2022;187:250-251.
    >> Share

  866. MORGAN CL, Thomas M, Stander S, Jabbar-Lopez ZK, et al
    Epidemiology of prurigo nodularis in England: a retrospective database analysis.
    Br J Dermatol. 2022;187:188-195.
    >> Share

    July 2022
  867. SCHNEIDER AM, Nelson AM
    Impaired epidermal barriers in congenital ichthyoses house a changing microbial landscape.
    Br J Dermatol. 2022 Jul 29. doi: 10.1111/bjd.21746.
    >> Share

  868. VAN DER SCHOOT LS, Atalay S, Otero ME, Kievit W, et al
    Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab.
    Br J Dermatol. 2022 Jul 27. doi: 10.1111/bjd.21797.
    >> Share

  869. WANG L, Rocas D, Dalle S, Sako N, et al
    Primary cutaneous peripheral T-cell lymphomas with a T follicular helper phenotype: An integrative clinical, pathological, and molecular case series study.
    Br J Dermatol. 2022 Jul 27. doi: 10.1111/bjd.21791.
    >> Share

  870. SHARIATMADARI I, Matteucci P, Barreda A, O'Toole L, et al
    Response to 'British Association of Dermatologists guidelines for the management of adults with basal cell carcinoma 2021': Vismodegib and indications for its use.
    Br J Dermatol. 2022 Jul 23. doi: 10.1111/bjd.21788.
    >> Share

  871. ORMEROD AD
    Predicting the outcome of psoriasis treatment.
    Br J Dermatol. 2022 Jul 22. doi: 10.1111/bjd.21747.
    >> Share

  872. VISCONTI A, Murray B, Rossi N, Wolf J, et al
    Cutaneous Manifestations of SARS-CoV-2 infection during the Delta and Omicron waves in 348,691 UK users of the UK ZOE COVID Study App.
    Br J Dermatol. 2022 Jul 22. doi: 10.1111/bjd.21784.
    >> Share

  873. LAURENT C, Lefevre G, Kahn JE, Staumont-Salle D, et al
    Cutaneous manifestations of lymphoid-variant hypereosinophilic syndrome.
    Br J Dermatol. 2022 Jul 21. doi: 10.1111/bjd.21782.
    >> Share

  874. NIKOLAOU V, Apalla Z, Carrera C, Fattore D, et al
    Clinical associations and classification of immune checkpoint inhibitors-induced cutaneous toxicities: A multicentric study from the EADV-Task Force of Dermatology for Cancer Patients.
    Br J Dermatol. 2022 Jul 21. doi: 10.1111/bjd.21781.
    >> Share

  875. CHOON SE, Wright AK, Griffiths CEM, Tey KE, et al
    Incidence and prevalence of psoriasis in multi-ethnic Johor Bahru, Malaysia: a population-based cohort study using electronic health data routinely captured in Teleprimary Care (TPC(R)) clinical information system from 2010 to 2020.
    Br J Dermatol. 2022 Jul 13. doi: 10.1111/bjd.21768.
    >> Share

  876. NAGTZAAM IF, van Leersum FS, Kouwenberg LCM, Blok MJ, et al
    STS pathogenic variants in a Dutch patient cohort clinically suspected for X-linked ichthyosis shows genetic heterogeneity.
    Br J Dermatol. 2022 Jul 13. doi: 10.1111/bjd.21775.